Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-17-166631.txt : 20170511 0001193125-17-166631.hdr.sgml : 20170511 20170511080157 ACCESSION NUMBER: 0001193125-17-166631 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170511 DATE AS OF CHANGE: 20170511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 17832569 BUSINESS ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 10-Q 1 d382380d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number: 001-37923

CRISPR THERAPEUTICS AG

(Exact name of Registrant as specified in its charter)


Switzerland		Not Applicable
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Aeschenvorstadt 36 4051 Basel, Switzerland		Not Applicable
(Address of principal executive offices)		(zip code)

+41 61 228 7800

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

As of May 8, 2017, there were 39,997,525 shares of registrant’s common shares outstanding.

Index


	Page Number
PART I: FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (unaudited)
Condensed Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016		2
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2017 and 2016		3
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2017 and 2016		4
Notes to Condensed Consolidated Financial Statements		5

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		18

Item 3. Quantitative and Qualitative Disclosures about Market Risk		27

Item 4. Controls and Procedures		27

PART II: OTHER INFORMATION

Item 1. Legal Proceedings		28

Item 1A. Risk Factors		29

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		29

Item 6. Exhibits		29

SIGNATURES		30

PART I—FINANCIAL INFORMATION

Item 1.

Financial Statements

CRISPR Therapeutics AG

Condensed Consolidated Balance Sheets

(unaudited, in thousands, except share and per share data)


	March 31,			December 31,
	2017			2016
Assets
Current assets:
Cash	$	288,872		$	315,520
Accounts receivable, including related party amounts of $1,057 and $752 as of March 31, 2017 and December 31, 2016, respectively		5,672			3,157
Prepaid expenses and other current assets including related party amounts of $577 and $0 as of March 31, 2017 and December 31, 2016, respectively		1,918			1,511

Total current assets		296,462			320,188
Property and equipment, net		22,165			21,027
Intangible assets, net		385			399
Restricted cash		3,151			3,150
Other non-current assets		183			198

Total assets	$	322,346		$	344,962

Liabilities and shareholders’ equity
Current liabilities:
Accounts payable	$	3,937		$	4,569
Accrued expenses, including related party amounts of $219 and $537 as of March 31, 2017 and December 31, 2016, respectively		11,699			16,320
Accrued tax liabilities		190			23
Deferred rent		1,027			1,027
Other current liabilities		62			59

Total current liabilities		16,915			21,998
Deferred revenue, including related party amounts of $420 and $527 as of March 31, 2017 and December 31, 2016, respectively		78,311			77,646
Deferred rent non-current		11,768			12,283
Other non-current liabilities		177			189

Total liabilities		107,171			112,116

Commitments and contingencies (Note 6)
Shareholders’ equity:
Common shares, CHF 0.03 par value		1,216			1,216
Treasury shares, at cost, 444,873 shares at March 31, 2017 and December 31, 2016		—			—
Additional paid-in capital		292,519			288,739
Accumulated deficit		(78,558	)		(57,083	)
Accumulated other comprehensive loss		(2	)		(26	)

Total shareholders’ equity		215,175			232,846

Total liabilities and shareholders’ equity	$	322,346		$	344,962

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CRISPR Therapeutics AG

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited, in thousands, except share and per share data)


	Three Months Ended
	March 31,
	2017			2016
Collaboration revenue (1)	$	2,703		$	476
Operating expenses:
Research and development (2)		14,805			6,012
General and administrative		8,642			6,116

Total operating expenses		23,447			12,128

Loss from operations		(20,744	)		(11,652	)

Other (expense) income:
Interest expense		—			(8,050	)
Loss from equity method investment		(446	)		—
Gain on extinguishment of convertible loan		—			11,482
Other expense, net		(6	)		(146	)

Total other (expense) income, net		(452	)		3,286

Net loss before income taxes		(21,196	)		(8,366	)

Provision for income taxes		(279	)		(76	)

Net loss		(21,475	)		(8,442	)
Foreign currency translation adjustment		24			(4	)

Comprehensive loss	$	(21,451	)	$	(8,446	)

Reconciliation of net loss to net loss attributable to common shareholders:
Net loss	$	(21,475	)	$	(8,442	)
Loss attributable to noncontrolling interest		—			3

Net loss attributable to common shareholders	$	(21,475	)	$	(8,439	)

Net loss per share attributable to common shareholders—basic and diluted	$	(0.54	)	$	(1.53	)

Weighted-average common shares outstanding used in net loss per share attributable to common shareholders—basic and diluted		39,725,947			5,528,079

(1) Including the following amounts of revenue from a related party, see Note 11:	$	1,164		$	—
(2) Including the following amounts of research and development expense with a related party, see Note 11:	$	1,136		$	269

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CRISPR Therapeutics AG

Condensed Consolidated Statements of Cash Flows

(unaudited, in thousands)


	Three Months Ended
	March 31,
	2017			2016
Operating activities:
Net loss	$	(21,475	)	$	(8,442	)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization		720			106
Equity-based compensation		3,746			1,022
Non-cash interest expense		—			8,050
Loss from disposal of property and equipment		—			28
Unrealized foreign currency remeasurement loss		1			11
Gain on extinguishment of convertible loan		—			(11,482	)
Changes in:
Restricted cash		(1	)		(2	)
Accounts receivable		(2,515	)		(626	)
Prepaid expenses and other assets		(394	)		(993	)
Accounts payable and accrued expenses		(3,648	)		1,956
Deferred revenue		665			151
Deferred rent		(515	)		172
Other liabilities, net		4			35

Net cash used in operating activities		(23,412	)		(10,014	)

Investing activities:
Purchase of property and equipment		(3,285	)		(232	)
Proceeds from contribution of intellectual property to equity method investee		—			20,000
Cash investment in equity method investee		—			(100	)

Net cash (used in) provided by investing activities		(3,285	)		19,668

Financing activities:
Proceeds from exercise of options		20			—
Proceeds from issuance of convertible loans		—			35,000

Net cash provided by financing activities		20			35,000

Effect of exchange rate changes on cash		29			(15	)
(Decrease) increase in cash		(26,648	)		44,639

Cash, beginning of period		315,520			155,961

Cash, end of period	$	288,872		$	200,600

Supplemental disclosure of non-cash investing and financing activities
Property and equipment purchases in accounts payable and accrued expenses	$	973		$	116

Conversion of Vertex convertible loan and accrued interest	$	—		$	61,929

Noncash contribution of intellectual property to Casebia LLP	$	—		$	36,372

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

CRISPR Therapeutics AG

Notes to Condensed Consolidated Financial Statements

(unaudited)

1. Organization and Operations

The Company

CRISPR Therapeutics AG (“CRISPR” or the “Company”) was formed on October 28, 2013 in Basel, Switzerland. The Company was established to translate CRISPR/Cas9, a genome editing technology, into transformative gene-based medicines for the treatment of serious human diseases. The foundational intellectual property underlying the Company’s operations was licensed to the Company and its subsidiaries in April 2014. The Company devotes substantially all of its efforts to product research and development activities, initial market development and raising capital. The Company’s principal offices are located in Basel, Switzerland and its principal research operations are in Cambridge, Massachusetts.

On January 23, 2014, the founders of the Company formed TRACR Hematology Limited (“TRACR”) in the United Kingdom, to further the development of the CRISPR/Cas9 technology into medicines for the treatment of blood-borne illnesses. As the Company was funding and managing TRACR’s operations in 2014, it has been consolidated by the Company from the date that the Company established a variable interest in TRACR in April 2014. In March 2015, the Company acquired 82.1% of the outstanding equity of TRACR in a share exchange transaction. Concurrent with its initial public offering (“IPO”) in October 2016, the Company acquired the outstanding non-controlling interest in TRACR, and as such, as of March 31, 2017, TRACR is a wholly-owned subsidiary of the Company.

On February 7, 2014, the Company formed a wholly-owned subsidiary in the United Kingdom, CRISPR Therapeutics Limited (“CRISPR Ltd.”), and on February 16, 2015, the Company formed a wholly-owned subsidiary in the United States, CRISPR Therapeutics, Inc. (“CRISPR Inc.”), as its principal research and development operation.

The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.

The Company had an accumulated deficit of $78.6 million as of March 31, 2017 and has financed its operations to date from proceeds obtained from its IPO, a series of preferred shares and convertible loan issuances, and upfront fees received under its collaboration and joint venture arrangements. The Company will require substantial additional capital to fund its research and development and ongoing operating expenses.

Liquidity

The Company expects its cash of $288.9 million at March 31, 2017 to be sufficient to fund its current operating plan for at least the next 24 months. Thereafter, the Company may be required to obtain additional funding. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (the “Annual Report”). There have been no material changes to the significant accounting policies during the three months ended March 31, 2017.

Unaudited Interim Financial Information

The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Annual Report.

Basis of Presentation and Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP, and include the accounts of (i) the Company, and (ii) its wholly-owned subsidiaries, CRISPR Ltd., CRISPR Inc., and TRACR. All intercompany accounts and transactions have been eliminated. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The Company accounts for its 50% investment in Casebia Therapeutics LLP (“Casebia”) under the equity method of accounting. See Note 7 for further details.

not limited to, equity-based compensation expense, revenue recognition, equity method investments, and reported amounts of expenses during the period. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, research and development expenses, equity-based compensation expense, fair value of intangible assets, and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Net Loss Per Share Attributable to Common Shareholders

Basic net income (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to common shareholders by the weighted-average number of common equivalent shares outstanding for the period, including any dilutive effect from outstanding stock options and warrants using the treasury stock method.

The following common share equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect (in common stock equivalent shares):


	Three Months Ended March 31,
	2017		2016
Convertible preferred shares		—		24,301,632
Dr. Emmanuelle Charpentier call option		—		328,017
Outstanding options		4,829,891		2,384,908
Unvested unissued restricted common shares		80,987		142,794

Total		4,910,878		27,157,351

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). Subsequently, the FASB also issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), which adjusted the effective date of ASU 2014-09; ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which amends the principal-versus-agent implementation guidance and illustrations in ASU 2014-09; ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies identifying performance obligation and licensing implementation guidance and illustrations in ASU 2014-09; and ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which addresses implementation issues and is intended to reduce the cost and complexity of applying the new revenue standard in ASU 2014-09 (collectively, the “Revenue ASUs”).

The Revenue ASUs noted above provide an accounting standard for a single comprehensive model for use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for interim and annual periods beginning after December 15, 2017, with an option to early adopt for interim and annual periods beginning after December 15, 2016. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (the full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company currently anticipates adopting the new standard effective January 1, 2018 under the full retrospective method. The Company is in the process of determining the impact of the Revenue ASUs on its financial statements as it relates to their two revenue generating collaboration agreements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”), which applies to all leases and will require lessees to record most leases on the balance sheet, but recognize expense in a manner similar to the current standard. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and interim periods within those years, which is the year ended December 31, 2019 for the Company. Entities are required to use a modified retrospective approach of adoption for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company is evaluating the new guidance and the expected effect on its consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”), to improve the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. Current guidance prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party, which is an exception to the principle of comprehensive recognition of current and deferred income taxes. The amendments in this update eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments should be applied on a modified retrospective transition basis, and are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The Company is evaluating the new guidance and the expected effect on its consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning and ending balances shown on the statement of cash flows. The guidance is effective in the first quarter of fiscal 2018 and early adoption is permitted. ASU 2016-18 must be applied retrospectively to all periods presented. Upon adoption, the Company’s 2016 statement of cash flows will reflect an increase in operating cash flows resulting from the adoption of this new standard. The Company does not expect any additional impact on its financial statements.

assets or businesses. The purpose of the guidance is to narrow the definition of a business at it relates recording transactions as business acquisitions or asset acquisitions. The guidance is effective in annual periods beginning after December 15, 2017, including interim periods within those years, with early adoption permitted under certain circumstances. The Company does not expect any additional impact on its financial statements.

In January 2017, the FASB issued ASU No. 2017-03, Accounting Changes and Error Corrections (Topic 250) and Investments—Equity Method and Joint Ventures (Topic 323) (“ASU 2017-03”). ASU No. 2017-03 amends topics 250 and 323 which were previously released. The effect of the amendment to these topics subsequently amended topics 326 – Measurement of Credit Losses on Financial Instruments, 606 – Revenue from Contracts with Customers, and 842 – Leases. This ASU was effective upon issuance. The adoption did not have a material impact on the Company’s financial statements.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment (“ASU 2017-04”). This new standard simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. The new standard became effective for the Company on January 1, 2017 and did not have a material impact on the Company’s financial statements.

3. Property and Equipment, net

Property and equipment, net, consists of the following (in thousands):


	As of
	March 31,			December 31,
	2017			2016
Computer equipment and software	$	110		$	110
Furniture, fixtures, and other		2,044			2,044
Laboratory equipment		4,728			2,970
Leasehold improvements		15,765			15,780
Construction work in process		1,165			1,065

		23,812			21,969
Accumulated Depreciation		(1,647	)		(942	)

Property and equipment, net	$	22,165		$	21,027

Depreciation expense was $0.7 million, and $0.1 million, for the three months ended March 31, 2017 and 2016, respectively.

4. Accrued Expenses

Accrued expenses consist of the following (in thousands):


	As of
	March 31, 2017		December 31, 2016
Payroll and employee-related costs	$	1,570	$	2,585
Research costs		490		996
Licensing fees		1,111		492
Professional fees		1,873		2,715
Intellectual property costs		1,700		3,372
Accrued property and equipment		4,697		5,081
Other		258		1,079

Total	$	11,699	$	16,320

5. Convertible Loans

2015 Convertible Loan Agreement with Vertex and certain existing shareholders

On October 26, 2015, the Company entered into a convertible loan agreement with Vertex Pharmaceuticals Incorporated (“Vertex”) and certain existing shareholders (the “Vertex Convertible Loan”) under which the Company borrowed $38.2 million. The Vertex Convertible Loan accrued interest at 2.5% per annum and had an initial maturity date of April 26, 2016 subject to acceleration upon the occurrence of certain conditions. The Vertex Convertible Loan included various embedded conversion, redemption and other features, none of which required separate accounting from the host instrument under ASC Topic 815: Derivatives and Hedging (“ASC 815”).

The conversion terms, redemption terms, and other features of the Vertex Convertible Loan are included in the Annual Report.

Convertible Loan with Bayer Global Investments B.V.

On January 29, 2016, concurrent with the execution of an agreement to establish a Joint Venture (“JV”) with Bayer HealthCare LLC (“Bayer HealthCare”), the Company entered into a Convertible Loan Agreement (the “Bayer Convertible Loan”) with Bayer Global Investments B.V. (“Bayer BV”) under which the Company borrowed $35.0 million. The Bayer Convertible Loan accrued interest at 2.0% per annum and matured on January 29, 2016. The Bayer Convertible Loan included various embedded conversion, redemption and other features, none of which required separate accounting from the host instrument under ASC 815.

The conversion terms, redemption terms, and other features of the Bayer Convertible Loan are included in the Annual Report.

Conversion of Convertible Loans to Series B Preferred Shares

On January 29, 2016, concurrent with the issuance of the Bayer Convertible Loan, all of the outstanding principal under the $35.0 million Bayer Convertible Loan automatically converted into 2,605,330 Series B Redeemable Convertible Preferred Shares (“Series B Preferred Shares”) at $13.43 per share. The Company determined the fair value of the Bayer Convertible Loan to be $24.5 million based on the fair value of the underlying Series B Preferred Shares that were exchanged as part of the immediate conversion. As the Bayer Convertible Loan was executed in contemplation of the joint venture agreement with Bayer, the Company evaluated the Bayer Convertible Loan as part of one multiple-element arrangement and, using a relative fair value allocation method, allocated $27.0 million of aggregate arrangement consideration to the Bayer Convertible Loan upon issuance. Upon conversion, the Company accreted the Bayer Convertible Loan to its face value of $35.0 million through a charge to interest expense of $8.0 million and converted the $35.0 million to Series B Preferred Shares under the conversion model.

The receipt of $35.0 million in proceeds under the Bayer Convertible Loan in exchange for equity securities, combined with the $38.2 million in proceeds from Vertex Convertible Loan, triggered an automatic conversion provision of the Vertex Convertible Loan Agreement. Accordingly, on January 29, 2016, the Vertex Convertible Loan, including loans from existing shareholders, plus accrued interest also converted into 2,859,278 of Series B Preferred Shares at $13.43 per share. The Company determined the fair value of the Vertex Convertible Loan to be $26.9 million based on the fair value of the underlying Series B Preferred Shares that were exchanged as part of the conversion. Upon extinguishment, the Company recorded a gain on extinguishment of $11.5 million for the difference between the carrying value of the debt and the fair value of the Series B Preferred Shares issued to settle the debt under the general extinguishment model.

6. Commitments and Contingencies

Operating Leases

In March 2017, the Company entered into a sublease for a portion of one research and office facility effective April 1, 2017. The sublease term is less than the remaining term under the original lease, and as a result, the Company does not believe it has met a cease use date as it may re-enter the space following the sublease. Net payments to be received under the sublease are consistent with scheduled rent payments under the original lease.

Litigation

The Company licenses a U.S. patent application that is currently subject to interference proceedings declared by the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office. Following motions by the parties and other procedural matters, the PTAB concluded in February 2017 that the declared interference should be dismissed because the claim sets of the two parties were not

directed to the same patentable invention in accordance with the PTAB’s two-way test for patent interferences. In April 2017, the Regents of the University of California (“California”) appealed the PTAB decision to the U.S. Court of Appeals for the Federal Circuit. In the appeal, California is seeking review and reversal of the PTAB’s February 2017 decision, which terminated the interference without determining which inventors actually invented the use of the CRISPR/Cas9 genome editing technology in eukaryotic cells.

Under the Invention Management Agreement signed on December 15, 2016, the Company is obligated to share costs related to patent maintenance, defense and prosecution. The Company incurred $0.5 million and $0.6 million, for the three months ended March 31, 2017 and 2016, respectively, in shared costs. The Company recorded accrued legal costs from the cost sharing of $0.9 million and $2.8 million as of March 31, 2017 and December 31, 2016, respectively.

7. Significant Contracts

Intellectual Property Agreements

CRISPR Therapeutics AG—Charpentier License Agreement

In April 2014, the Company entered into a technology license agreement with Dr. Charpentier pursuant to which the Company licensed certain intellectual property rights under joint ownership from Dr. Charpentier to develop and commercialize products for the treatment or prevention of human diseases other than hemoglobinopathies (“CRISPR—Charpentier License Agreement”). In consideration for the granting of the license, the Company paid Dr. Charpentier an upfront fee of CHF 0.1 million ($0.1 million), and agreed to pay an immaterial annual license maintenance fee if Dr. Charpentier is not otherwise engaged in a service arrangement with the Company. During the years ended December 31, 2016 and 2015, and three months ended March 31, 2017 and 2016, Dr. Charpentier has been in a consulting arrangement with the Company, as such, no annual payments have been made under this provision. Dr. Charpentier is entitled to receive nominal clinical milestone payments. The Company is also obligated to pay Dr. Charpentier a low single digit percentage of sublicensing payments received under any sublicense agreement with a third party. In addition, the Company is also obligated to pay to Dr. Charpentier a low single-digit percentage royalty based on annual net sales of licensed products and licensed services by the Company and its affiliates and sublicensees.

During the three months ended March 31, 2017 and 2016, the Company recorded $0 and $0.3 million, respectively, of sublicensing fees due to Dr. Charpentier. These expenses were under the terms of the CRISPR—Charpentier License Agreement that was triggered by the execution of the Bayer Agreement (“Bayer Agreement”).

TRACR Hematology Limited—Charpentier License Agreement

In April 2014, TRACR entered into a technology license agreement (“TRACR—Charpentier License Agreement”) with Dr. Charpentier pursuant to which TRACR licensed certain intellectual property rights under joint ownership from Dr. Charpentier to develop and commercialize products for the treatment or

prevention of human diseases related to hemoglobinopathies. In consideration for the granting of the license, Dr. Charpentier is entitled to receive nominal clinical milestone payments. TRACR is also obligated to pay Dr. Charpentier a low single digit percentage of sublicensing payments received under any sublicense agreement with a third party. In addition, TRACR is obligated to pay to Dr. Charpentier low single digit percentage royalties based on annual net sales of licensed products and licensed services by the Company and its affiliates and sublicensees.

During the three months ended March 31, 2017 and 2016, the Company did not record any sublicensing fees due to Dr. Charpentier under the terms of the TRACR—Charpentier License Agreement.

Patent Assignment Agreement

In November 2014, the Company entered into a patent assignment agreement (“Patent Assignment Agreement”) with Dr. Charpentier, Dr. Ines Fonfara, and the University of Vienna (collectively, the “Assignors”), pursuant to which the Company received from the assignors all rights, title and interest in and to certain patent rights claimed in the U.S. Patent Application No.61/905,835. In consideration for the assignment of such rights, the Assignors are entitled to receive clinical milestone payments totaling up to €0.3 million (approximately $0.4 million) in the aggregate for the first human therapeutic product. The Company is also obligated to pay to the Assignors low single digit royalties based on annual net sales of certain products and services by the Company and its affiliates and sublicensees.

During the three months ended March 31, 2017 and 2016, the Company recorded $0 and $19 thousand, respectively, of sublicensing fees due to the Assignors under the terms of the Patent Assignment Agreement that was triggered under the Vertex collaboration agreement and by the execution of the Bayer Agreement.

Collaboration Agreement with Vertex Pharmaceuticals, Incorporated

On October 26, 2015, the Company entered into a strategic collaboration, option, and license agreement (“Collaboration Agreement”) with Vertex, focused on the use of CRISPR’s gene editing technology, CRISPR/Cas9, to discover and develop potential new treatments aimed at the underlying genetic causes of human disease.

During the three months ended March 31, 2017 and 2016, the Company recognized $1.5 million and $0.5 million of revenue related to the collaboration with Vertex. Research and development expense incurred by the Company in relation to its performance under the Collaboration Agreement for the three months ended March 31, 2017 and 2016 was $2.6 million and $0.6 million, respectively. As of March 31, 2017 and December 31, 2016, there was $77.9 million and $77.1 million of non-current deferred revenue related to the Company’s collaboration with Vertex, respectively.

Joint Venture with Bayer Healthcare LLC

On December 19, 2015, the Company entered into an agreement with Bayer HealthCare LLC to establish the JV to discover, develop and commercialize new therapeutics to cure blood disorders, blindness, and

congenital heart disease. On February 12, 2016, the Company and Bayer HealthCare completed the formation of the joint venture entity, Casebia. CRISPR contributed its proprietary CRISPR/Cas9 gene editing technology and intellectual property for selected disease indications and Bayer HealthCare contributed its protein engineering expertise and relevant disease know-how.

At March 31, 2017 and December 31, 2016, the Company’s equity method investment in Casebia was zero.

During the three months ended March 31, 2017 and 2016, the Company recognized $1.2 million and $0 of revenue, respectively, related to the collaboration with Casebia. During the three months ended March 31, 2017 and 2016, the Company recognized $1.1 million and $0 of research and development expense, respectively, in relation to its performance under the agreement. During the three months ended March 31, 2017 and 2016, the Company recognized $0.5 million and $0, respectively, of stock-based compensation expense related to Casebia employees. Non-current deferred revenue related to the Company’s collaboration with Casebia was $0.4 million and $0.5 million as of March 31, 2017 and December 31, 2016, respectively. Unrecognized equity method losses in excess of the Company’s equity investment in Casebia was $6.5 million and $4.0 million as of March 31, 2017 and December 31, 2016, respectively.

Total operating expenses, and net loss of Casebia for the three months ended March 31, 2017 was $5.5 million. During the three months ended March 31, 2016, total operating expenses and net loss of Casebia was $73.8 million which included research and development expenses of $71.4 million for the fair value of the CRISPR license acquired.

8. Share Capital

The Company had 40,258,364 registered common shares as of March 31, 2017, with a par value of CHF 0.03 per share, which includes 80,987 shares of unvested unissued restricted common stock and 444,873 treasury shares which are legally outstanding but not considered outstanding for accounting purposes.

Conditional Capital Reserved for Future Issuance

The Company had the following conditional capital reserved for future issuance:


	As of
Conditional Capital	March 31, 2017		December 31, 2016
Unvested unissued restricted stock		166,667		166,667
Outstanding stock options		4,829,891		4,535,371
Reserved for future issuance under stock option plans		4,996,123		5,290,643
Shares available for bonds and similar debt instruments		4,919,700		4,919,700
Shares available for employee purchase plans		413,226		413,226

Total		15,325,607		15,325,607

9. Equity-based Compensation

The Company uses the straight-line attribution method to recognize stock-based compensation expense for stock options and restricted stock awards. Stock options and restricted stock awards generally vest over four years with 25% vesting on the first anniversary of service commencement and the remaining 75% vesting monthly thereafter. Effective January 1, 2017, the company adopted ASU No. 2016-09 (“ASU 2016-09”), and made an accounting policy election to account for the impact of pre-vesting forfeitures as they occur rather than applying an estimated forfeiture rate, as previously required. The following table presents stock-based compensation expense included in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss:


	Three Months Ended March 31,
	2017		2016
Research and development	$	1,730	$	638
General and administrative		1,570		384
Loss from equity method investment		446		—

Total	$	3,746	$	1,022

Grant-Date Fair Value

The Company estimated the fair value of each employee and non-employee stock option award on the grant date using the Black-Scholes option-pricing model based on the following assumptions:


	Three Months Ended March 31,
	2017			2016
Employees:
Weighted average expected volatility		73.0	%		77.5	%
Expected term (in years)		6.0			6.0
Risk free interest rate		2.2	%		1.5	%
Expected dividend yield		0.0	%		0.0	%

Non-employees:
Weighted average expected volatility		81.0	%		n/a
Expected term (in years)		10.0			n/a
Risk free interest rate		2.4	%		n/a
Expected dividend yield		0.0	%		n/a

The fair value of the restricted stock awards was determined based on the fair value of the common shares on the grant date. Non-employee stock options and restricted stock awards are marked-to-market at each reporting period.

Share Based Payment Activity

Stock Option Awards

The following table summarizes stock option activity for employees and non-employees (intrinsic value in thousands):


	Stock Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2016		4,535,371		$	8.38		9.1	$	53,966

Granted		440,032		$	20.78
Exercised		(4,690	)	$	4.24
Cancelled or forfeited		(140,822	)	$	5.14

Outstanding at March 31, 2017		4,829,891		$	9.59		9.0	$	58,960

Exercisable at March 31, 2017		1,289,490		$	4.27		8.6	$	22,568

Vested or expected to vest at March 31, 2017 (1)		4,755,902		$	9.51		9.0	$	58,417

(1)	Represents the number of vested options at March 31, 2017 plus options expected to vest in the future.

As of March 31, 2017, total unrecognized compensation expense related to stock options was $28.9 million which the Company expects to recognize over a remaining weighted-average period of 3.2 years.

During the three months ended March 31, 2017 and 2016, the Company granted options to purchase 15,000 and 13,333 common shares, respectively, subject to performance-based vesting conditions. As of March 31, 2017, options to purchase 284,372 common shares subject to performance-based vesting conditions were vested, as performance conditions were achieved, and no options to purchase common shares subject to performance-based vesting conditions were deemed probable of vesting.

Restricted Stock Awards

The following table summarizes restricted stock activity for employees and non-employees during the three months ended March 31, 2017:


	Reflected as outstanding upon vesting			Reflected as outstanding upon grant date			Total			Weighted- Average Grant Date Fair Value
Unvested restricted common shares as of December 31, 2016		89,367			650,856			740,223		$	3.84

Vested		(8,380	)		(106,000	)		(114,380	)		4.02

Unvested restricted common shares as of March 31, 2017		80,987			544,856			625,843		$	3.81

During the three months ended March 31, 2017, the total fair value of vested restricted common shares was $2.3 million. As of March 31, 2017, total unrecognized compensation expense related to unvested restricted common shares was $6.4 million which the Company expects to recognize over a remaining weighted-average period of 1.2 years.

The Company did not grant any restricted common shares subject to performance-based vesting conditions during the three months ended March 31, 2017. As of March 31, 2017, 50,000 restricted common shares subject to performance-based vesting conditions were vested.

During the year ended December 31, 2016, the Company and Fay Corp. transferred 290,400 common shares to a founder, 268,093 of which were subject to vesting conditions with a weighted average grant date fair value of $12.65 per share. The unvested common shares are subject to repurchase by the Company upon termination of the holder’s service relationship with the Company as well as upon certain triggering events such as termination for cause, material breach of agreement and insolvency of the holder. The Company recognized expense related to these common shares in the amount of $0.2 million and $0 during the three months ended March 31, 2017 and 2016, respectively.

10. Income Taxes

During the three months ended March 31, 2017 and 2016, the Company recorded an income tax provision of $0.3 million and $0.1 million, respectively, representing an effective tax rate of -1.3% and -0.9%, respectively. The income tax provision is primarily attributable to the year-to-date pre-tax income earned by the Company’s U.S. and U.K. subsidiaries. The difference in the statutory tax rate and effective tax rate is primarily a result of the jurisdictional mix of earnings and losses that are not benefited. The Company maintains a valuation allowance against certain deferred tax assets that are not more-likely-than-not realizable. As a result, the Company has not recognized a tax benefit related to the Swiss losses generated in the current periods.

11. Related Party Transactions

The Company is a party to intellectual property license agreements with Dr. Charpentier. As of March 31, 2017 and December 31, 2016, the Company owed Dr. Charpentier approximately $0.2 million and $0.5 million, respectively, of sublicense fees primarily related to the Bayer Agreement. During the three months ended March 31, 2017 and 2016, the Company recorded sublicensing fees of $0 and $0.3 million, respectively, due to Dr. Charpentier in research and development expense related to the Bayer Agreement.

The Company is a party to the JV with Bayer HealthCare. During the three months ended March 31, 2017 and 2016, the Company recognized revenue of $1.2 million and $0, respectively, related to the collaboration with Casebia. During the three months ended March 31, 2017, and 2016, the Company recognized $1.1 million and $0 of research and development expense, respectively, related to the performance of services for Casebia. As of March 31, 2017 and December 31, 2016, the Company recorded accounts receivable of $1.1 million and $0.8 million, respectively, other current assets of $0.6 million and $0, respectively, and deferred revenue of $0.4 million and $0.5 million, respectively, related to Casebia.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with (i) our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and (ii) our audited consolidated financial statements and related notes and management’s discussion and analysis of financial condition and results of operations included in our annual report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission on March 10, 2016. This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” “would” or the negative or plural of these words or similar expressions or variations. Such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors”, set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other SEC filings. You should not rely upon forward-looking statements as predictions of future events. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Overview

We are a leading gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR) Associated Protein 9 and is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The application of CRISPR/Cas9 for gene editing was co-invented by one of our scientific founders, Dr. Charpentier, who, along with her collaborators, published work elucidating how CRISPR/Cas9, a naturally occurring viral defense mechanism found in bacteria, can be adapted for use in gene editing. We are applying this technology to potentially treat a broad set of rare and common diseases by disrupting, correcting or regulating the genes related to the disease. We believe that our scientific expertise, together with our approach, may enable an entirely new class of highly active and potentially curative treatments for patients for whom current biopharmaceutical approaches have had limited success.

Since our inception in October 2013, we have devoted substantially all of our resources to initiating the conduct of our research and development efforts, identifying potential product candidates, undertaking drug discovery and preclinical development activities, building and protecting our intellectual property portfolio, organizing and staffing our company, business planning, raising capital, and providing general and administrative support for these operations. To date, we have primarily financed our operations through the initial public offering (“IPO”) of our common shares, private placements of our preferred and common shares, convertible loans and collaboration agreements with strategic partners. From our inception through March 31, 2017, we raised an aggregate of $397.1 million of which $53.7 million consisted of proceeds from our IPO, $35.0 million from a private placement of our

common shares, $125.2 million of gross proceeds from private placements of preferred shares, $73.2 million from the issuance of convertible loans, $75.0 million from an upfront payment under our collaboration with Vertex Pharmaceuticals, Incorporated, or Vertex, and $35.0 million from a technology access fee related to our license of technology to Casebia Therapeutics, LLP, our joint venture, or JV, with Bayer HealthCare LLC, or Bayer HealthCare.

In October 2016, we issued 4,429,311 of our common shares, including 429,311 common shares sold pursuant to the underwriters’ partial exercise of their option to purchase additional common shares, in our IPO, at a public offering price of $14.00 per share, for aggregate gross proceeds of approximately $62.0 million. Concurrent with the IPO, we issued an aggregate of 2,500,000 common shares to Bayer Global Investments BV, or Bayer BV, in a private placement, at the IPO price of $14.00 a share, for aggregate net proceeds of $35.0 million.

All of our revenue to date has been collaboration revenue. We have incurred significant net operating losses in every year since our inception and expect to continue to incur net operating losses for the foreseeable future. As of March 31, 2017, we had $288.9 million in cash and an accumulated deficit of $78.6 million. We expect to continue to incur significant expenses and increasing operating losses for the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase significantly as we continue our current research programs and development activities; seek to identify additional research programs and additional product candidates, conduct preclinical studies enabling clinical trial applications and initiate clinical trials for our most advanced product candidates which are from our hemoglobinopathy program targeting both beta thalassemia and sickle cell disease; initiate preclinical testing and clinical trials for any other product candidates we identify and develop, maintain, expand and protect our intellectual property portfolio, further develop our gene editing platform; hire additional research, clinical and scientific personnel; acquire or in license other technologies; and incur additional costs associated with operating as a public company.

Collaboration Agreement and Joint Venture Agreement

In October 2015, we entered into a strategic research collaboration agreement with Vertex focused on the development of CRISPR/Cas9-based therapies. Under the terms of our agreement, we received an upfront, nonrefundable payment of $75.0 million and proceeds from a convertible loan of $30 million.

In December 2015, we entered into a joint venture agreement, or the JV Agreement, with Bayer HealthCare to create a joint venture, Casebia, to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness and heart disease. We and Bayer HealthCare each have a 50% interest in the JV. Under the JV Agreement, Bayer HealthCare is making available its protein engineering expertise and relevant disease know-how and we are contributing our proprietary CRISPR/Cas9 gene editing technology and intellectual property. Bayer HealthCare will also provide up to $300.0 million in research and development investments to the JV over the first five years, subject to specified conditions.

In connection with the JV Agreement, the JV was required to pay us a technology access fee of $35.0 million consisting of an upfront payment of $20.0 million, which was paid at the closing of the JV Agreement in March 2016, and another payment of $15.0 million for specified intellectual property rights relating to our CRISPR/Cas9 technology outside of the United States, which was paid in December 2016. In January 2016, we also issued a convertible loan to Bayer BV (the “Bayer Convertible Loan”) for gross proceeds of $35.0 million which was immediately converted to Series B Preferred Shares at a conversion price of $13.43 per share. Concurrent with the IPO in October 2016, we issued 2,500,000 common shares to Bayer BV, at the IPO price of $14.00 per share resulting in aggregate net proceeds of $35.0 million.

Financial Overview

Revenue

We have not generated any revenue to date from product sales and do not expect to do so in the future. During the three months ended March 31, 2017 and 2016, we recognized revenue related to our collaboration agreements with Vertex and Casebia in the aggregate amount of $2.7 million and $0.5 million, respectively. As of March 31, 2017, we had not received any milestone or royalty payments under the Vertex collaboration agreement. For additional information about our revenue recognition policy, see the “Critical Accounting Policies and Estimates—Revenue” in our Annual Report.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our product discovery efforts and the development of our product candidates, which include:

•

employee-related expenses, including salaries, benefits and equity-based compensation expense;

•

costs of services performed by third parties that conduct research and development and preclinical activities on our behalf;

•

costs of purchasing lab supplies and non-capital equipment used in our preclinical activities and in manufacturing preclinical study materials;

•

consultant fees;

•

facility costs, including rent, depreciation and maintenance expenses; and

•

fees and other payments related to acquiring and maintaining licenses under our third-party licensing agreements.

Research and development costs are expensed as incurred. Nonrefundable advance payments for research and development goods or services to be received in the future are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. At this time, we cannot reasonably estimate or know the nature, timing or estimated costs of the efforts that will be necessary to complete the development of any product candidates we may develop. This is due to the numerous risks and uncertainties associated with developing such product candidates, including the uncertainty of:

•

successful completion of preclinical studies and Investigational New Drug-enabling studies;

•

successful enrollment in, and completion of, clinical trials;

•

receipt of marketing approvals from applicable regulatory authorities;

•

establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;

•

obtaining and maintaining patent and trade secret protection and non-patent exclusivity;

•

launching commercial sales of the product, if and when approved, whether alone or in collaboration with others;

•

acceptance of the product, if and when approved, by patients, the medical community and third-party payors;

•

effectively competing with other therapies and treatment options;

•

a continued acceptable safety profile following approval;

•

enforcing and defending intellectual property and proprietary rights and claims; and

•

achieving desirable medicinal properties for the intended indications.

A change in the outcome of any of these variables with respect to the development of any product candidates or the subsequent commercialization of any product candidates we may successfully develop could significantly change the costs, timing and viability associated with the development of that product candidate.

Except for activities we perform in connection with our collaborations with Vertex and Casebia, we do not track research and development costs on a program-by-program basis. We plan to track research and development costs for individual development programs when we identify a product candidate from the program that we believe we can advance into clinical trials.

Research and development activities are central to our business model. We expect research and development costs to increase significantly for the foreseeable future as our current development programs progress and new programs are added.

General and Administrative Expenses

General and administrative expenses consist primarily of employee related expenses, including salaries, benefits, and equity-based compensation for personnel in executive, finance, accounting, business development and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.

We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities, potential commercialization of our product candidates and increased costs of operating as a public company. We anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with exchange listing and SEC requirements, insurance costs and investor relations costs, the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. We also anticipate increased expenses related to the reimbursements of third-party patent related expenses with respect to certain of our in-licensed intellectual property.

Results of Operations

Comparison of three Months Ended March 31, 2017 and 2016

The following table summarizes our results of operations for the three months ended March 31, 2017 and 2016, together with the dollar change in those items:


	March 31,						Period Change
	2017			2016			Period Change
	(in thousands)
Collaboration revenue	$	2,703		$	476		$	2,227
Operating expenses:
Research and development		14,805			6,012			8,793
General and administrative		8,642			6,116			2,526

Total operating expenses		23,447			12,128			11,319

Loss from operations		(20,744	)		(11,652	)		(9,092	)
Other (expense) income, net		(452	)		3,286			(3,738	)

Net loss before income taxes		(21,196	)		(8,366	)		(12,830	)
Provison for income taxes		(279	)		(76	)		(203	)

Net loss	$	(21,475	)	$	(8,442	)	$	(13,033	)

Collaboration Revenue

Collaboration revenue for the three months ended March 31, 2017 was $2.7 million, compared to $0.5 million for the three months ended March 31, 2016. The increase of $2.2 million was primarily due to an increase of research and development service revenue from the collaboration with Vertex of $1.0 million, and research and development service revenue of $1.2 million under a collaboration agreement with Casebia.

Research and Development Expenses

Research and development expenses for the three months ended March 31, 2017 was $14.8 million, compared to $6.0 million for the three months ended March 31, 2016. The increase of $8.8 million was primarily attributable to the following increases: $1.6 million of facilities costs including rent and utilities at our enlarged research facility, $3.3 million of variable process and platform development costs, $2.6 million of employee-related costs, $1.1 million of employee stock based compensation costs and $0.2 million increase in license fees.

General and Administrative Expenses

General and administrative expenses were $8.6 million for the three months ended March 31, 2017, compared to $6.1 million for the three months ended March 31, 2016. The increase of $2.5 million was primarily due to the following increases: $1.2 million of employee-related costs to support our overall growth, $1.2 million of employee stock based compensation, $0.7 million in facilities costs including rent

and utilities at our enlarged research facility, and $0.4 million of professional and consulting expenses including legal. These increases were partially offset by a $1.0 million decrease of intellectual property costs, including third-party costs to procure the issuance of patents in jurisdictions outside the United States, and costs related to an interference proceeding with respect to our in-licensed intellectual property.

Other (Expense) Income, Net

Other (expense) income, net, was $0.5 million of expense for the three months ended March 31, 2017, compared to $3.3 million of income for the three months ended March 31, 2016. The decrease of $3.7 million was primarily due $0.4 million of loss from equity method investment recognized in the three months ended March 31, 2017, as compared to a gain of $11.4 million on the extinguishment of convertible loans with Vertex, offset by $8.1 million of interest expense related to the convertible loan with Bayer recognized in the three months ended March 31, 2016.

Liquidity and Capital Resources

From our inception through March 31, 2017, we raised an aggregate of $397.1 million, of which $53.7 million consisted of proceeds from our IPO, $35.0 million from a private placement of our common shares, $125.2 million of gross proceeds from private placements of preferred shares, $73.2 million from the issuance of convertible loans, an up-front payment under our collaboration agreement with Vertex of $75.0 million, and a technology access fee of $35.0 million from Casebia, pursuant to our JV Agreement with Bayer HealthCare.

As of March 31, 2017, we had $288.9 million in cash of which approximately $281.6 million was held outside of the United States.

Funding Requirements

Our primary uses of capital are, and we expect will continue to be, research and development activities, compensation and related expenses, laboratory and related supplies, legal and other regulatory expenses, patent prosecution filing and maintenance costs for our licensed intellectual property and general overhead costs. We expect our expenses to increase compared to prior periods in connection with our ongoing activities, particularly as we continue research and development and preclinical activities, including preclinical studies to support clinical trial applications, and we initiate clinical trial. In addition, we expect to incur additional costs associated with operating as a public company.

Because our research programs are still in preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of any future product candidates or whether, or when, we may achieve profitability. Until such time as we can generate substantial product revenues, if ever, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. We are entitled to research payments under our collaboration with Vertex. Additionally, we are eligible to earn payments, in each case, on a per-product basis under the JV Agreement and our collaboration with Vertex and Casebia. Except for these sources of funding, we do not have any committed external source of liquidity. To the extent that we raise additional capital through the future sale of equity or convertible debt securities, the ownership interest of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing shareholders. If we raise additional funds through collaboration arrangements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Outlook

Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that the net proceeds from our IPO, including the proceeds from the concurrent private placement with Bayer BV, together with our existing cash, will enable us to fund our operating expenses and capital expenditures for at least the next 24 months, without giving effect to any additional proceeds we may receive under our collaboration agreement with Vertex and the JV. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect.

Our ability to generate revenue and achieve profitability depends significantly on our success in many areas, including: developing our delivery technologies and our CRISPR/Cas9 technology platform; selecting appropriate product candidates to develop; completing research and preclinical and clinical development of selected product candidates; obtaining regulatory approvals and marketing authorizations for product candidates for which we complete clinical trials; developing a sustainable and scalable manufacturing process for product candidates; launching and commercializing product candidates for which we obtain regulatory approvals and marketing authorizations, either directly or with a collaborator or distributor; obtaining market acceptance of our product candidates; addressing any competing technological and market developments; negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; maintaining good relationships with our collaborators and licensors; maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and attracting, hiring and retaining qualified personnel.

Cash Flows

The following table provides information regarding our cash flows for each of the period below:


	March 31,						Period Change
	2017			2016			Period Change
	(in thousands)
Net cash used in operating activities	$	(23,412	)	$	(10,014	)	$	(13,398	)
Net cash (used in) provided by investing activities		(3,285	)		19,668			(22,953	)
Net cash provided by financing activities		20			35,000			(34,980	)
Effect of exchange rate changes on cash		29			(15	)		44

Net (decrease) increase in cash	$	(26,648	)	$	44,639		$	(71,287	)

Net Cash Used in Operating Activities

Net cash used in operating activities was $23.4 million for the three months ended March 31, 2017 as compared to $10.0 million for the three months ended March 31, 2016. The net cash used in operating activities for the three months ended March 31, 2017 primarily consisted of a net loss of $21.5 million adjusted for non-cash items (including equity-based compensation expense of $3.7 million, and depreciation and amortization expense of $0.7 million), an increase in accounts receivable of $2.5 million, an increase in prepaid expenses and other assets of $0.4 million and a decrease in accounts payable and accrued expenses of $3.6 million, and a decrease of $0.5 million in deferred rent, partially offset by an increase in deferred revenue of $0.7 million.

Net Cash (Used in) Provided by Investing Activities

Net cash used in investing activities for the three months ended March 31, 2017 was $3.3 million as compared with net cash provided by investing activities for the three months ended March 31, 2016 of $19.7 million. The net cash used in investing activities for the three months ended March 31, 2017 consisted primarily of purchases of property and equipment for use in research and development activities. We expect purchases of property and equipment to continue to increase in 2017 and 2018 as we build-out and outfit the office and laboratory space we began to occupy in December 2016.

Net Cash Provided by Financing Activities

Net cash provided by financing activities for the three months ended March 31, 2017 was $20 thousand, compared with $35.0 million for the three months ended March 31, 2016. The net cash provided by financing activities for the three months ended March 31, 2017 consisted of proceeds from the exercise of stock options. The cash provided by financing activities for the three months ended March 31, 2016 consisted of the proceeds from our subscription agreement with Bayer BV.

Contractual Obligations

We enter into agreements in normal course of business with vendors for preclinical research studies and other services and products for operating purposes.

We have engaged several research institutions to identify new delivery strategies and applications of the CRISPR/Cas9 technology. As a result of these efforts, we sponsored three research programs during the three months ended March 31, 2017. We have committed spending in one of these programs through 2018.

We have long-term liabilities associated with uncertain tax positions recorded under ASC 740, Income Taxes totaling $0.2 million. Due to the complexity associated with tax uncertainties, we cannot reasonably make a reliable estimate of the period in which we expect to settle these non-current liabilities. See Note 10 of the unaudited condensed consolidated financial statements contained in Item 1 of this interim report for more information on our unrecognized tax benefits.

Under the Invention Management Agreement (“IMA”) signed on December 15, 2016, the Company is obligated to share costs related to patent maintenance, defense and prosecution for the CRISPR/Cas9 gene editing intellectual property with California, Vienna and their licensees including Caribou Biosciences, Inc. and Caribou’s licensee Intellia Therapeutics, Inc.

Off-Balance Sheet Arrangements

As of March 31, 2017, we do not have any off-balance sheet arrangements as defined under applicable SEC rules.

Critical Accounting Policies and Significant Judgments and Estimates

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates—which also would have been reasonable—could have been used. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that our most critical accounting policies are those relating to revenue recognition, variable interest entities and equity-based compensation, and there have been no significant changes to our accounting policies discussed in the Annual Report.

Recent Accounting Pronouncements

Refer to Note 2, “Summary of Significant Accounting Policies,” in the accompanying notes to the consolidated financial statements for a discussion of recent accounting pronouncements. There were no new accounting pronouncements adopted during 2017 that had a material effect on our financial statements.

Item 3.

Qualitative and Quantitative Disclosures about Market Risk

Foreign Exchange Market Risk

As a result of our foreign operations, we face exposure to movements in foreign currency exchange rates, primarily the Swiss Franc and British Pound, against the U.S. dollar. The current exposures arise primarily from cash, accounts payable, and intercompany receivables and payables. Changes in foreign exchange rates affect our consolidated statement of operations and distort comparisons between periods. We do not engage in any foreign exchange rate hedging activities and therefore we are subject to foreign currency impacts.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2017. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2017, our Chief Executive Officer and Principal Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings.

From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. There are currently no claims or actions pending against us that, in the opinion of our management, are likely to have a material adverse effect on our business.

In January 2016, the U.S. Patent and Trademark Office, or USPTO, declared an interference between one of the pending U.S. patent applications we have in-licensed from Dr. Charpentier and twelve issued U.S. patents owned jointly by the Broad Institute and Massachusetts Institute of Technology and, in some instances, the President and Fellows of Harvard College, which we refer to individually and collectively as Broad. The interference was redeclared in March 2016 to add a U.S. patent application owned by Broad. An interference is a proceeding conducted at the USPTO by the Patent Trial and Appeal Board, or PTAB, to determine which party was the first to invent subject matter claimed by at least two parties. There were two parties to this interference being Dr. Charpentier, the Regents of the University of California, and the University of Vienna (collectively, “UC”) and the Broad.

Following motions by the parties and other procedural matters, in February 2017 the PTAB concluded that the declared interference should be dismissed. In its decision, the PTAB concluded that, although the claims overlap, the respective scope of UC and Broad’s claim sets as presented did not define the same patentable invention and, accordingly, terminated the interference.

In April 2017, UC appealed the PTAB decision to the U.S. Court of Appeals for the Federal Circuit, or the Federal Circuit. In the appeal, UC is seeking review and reversal of the PTAB’s February 2017 decision, which terminated the interference without determining which inventors actually invented the use of the CRISPR/Cas9 genome editing technology in eukaryotic cells.

In addition to the appeal of the PTAB decision to the Federal Circuit, in parallel, either party can also pursue existing or new patent applications in the U.S. and elsewhere. Going forward, either party and other parties could seek a new interference related to the uses of the technology in eukaryotic cells or other aspects of the technology, and any existing or new patents could be the subject of other challenges to their validity of enforceability. If there is a second interference, either party could again appeal an adverse decision to the U.S. Court of Appeals for the Federal Circuit.

In any case, it may be years before there is a final determination on priority. Pursuant to the terms of the license agreement with Dr. Charpentier, we are responsible for covering or reimbursing Dr. Charpentier’s patent prosecution, defense and related costs associated with our in-licensed technology.

Item 1A.

Risk Factors.

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

Use of Proceeds

For the three months ended March 31, 2017, we estimate that we used approximately $45.9 million of the net proceeds from the IPO as follows: approximately $25.2 million on research and development activities to advance our product candidates; and approximately $20.7 million for working capital and general corporate purposes. None of the offering expenses consisted of direct or indirect payments made by us to directors, officers or persons owning 10% or more of our common stock or to their associates, or to our affiliates. There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on October 19, 2016 pursuant to Rule 424. As of March 31, 2017, we had not invested the unused proceeds from the offering.

Item 6.

Exhibits

The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Form 10-Q.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	CRISPR Therapeutics AG

Dated: May 11, 2017	By:	/s/ Rodger Novak
		Rodger Novak
		Chief Executive Officer
		(Principal Executive Officer)

Dated: May 11, 2017	By:	/s/ Samarth Kulkarni
		Samarth Kulkarni
		President and Chief Business Officer
		(Principal Financial Officer)


Exhibit Number		Description of Document

31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		Financials in XBRL format.

The certification attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of CRISPR Therapeutics AG under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

EX-31.1 2 d382380dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Rodger Novak, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of CRISPR Therapeutics AG;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2017


By:		/s/ Rodger Novak
		Rodger Novak
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 d382380dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Samarth Kulkarni, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of CRISPR Therapeutics AG;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2017


By:		/s/ Samarth Kulkarni
		President and Chief Business Officer
		(Principal Financial Officer)

EX-32.1 4 d382380dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of CRISPR Therapeutics AG (the “Company”) for the period ended March 31, 2017 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

/s/ Rodger Novak

Rodger Novak

Chief Executive Officer

(Principal Executive Officer)

May 11, 2017

/s/ Samarth Kulkarni

Samarth Kulkarni

President and Chief Business Officer

(Principal Financial Officer)

May 11, 2017

EX-101.INS 5 crsp-20170331.xml XBRL INSTANCE DOCUMENT 300000 400000 39997525

0.821

200600000

800000

500000 0

1570000

0.03

288872000

1647000

322346000

11768000

1027000

1057000

296462000

40258364

292519000

288872000

5672000

1216000

78311000

15325607

3937000

1873000

-2000

11699000

62000

107171000

322346000

385000

177000

16915000

258000

183000

22165000

23812000

215175000

28900000

190000

-78558000

444873

1918000

3151000

490000 1111000 420000 1700000 219000 4697000 577000

4996123

6400000

625843

3.81

544856

80987

4829891

166667

77900000

80987

1165000

15765000

110000

4728000

2044000

4919700

58960

4.27

9.59

1289490

58417

22568

4755902

9.51

4829891

200000

1100000

400000 600000

0.50

400000

413226

155961000

13.43

26900000

0.020

35000000

13.43

24500000

27000000

2585000

0.03

315520000

942000

344962000

12283000

1027000

752000

320188000

288739000

315520000

3157000

1216000

77646000

15325607

4569000

2715000

-26000

16320000

59000

112116000

344962000

399000

189000

21998000

1079000

198000

21027000

21969000

232846000

23000

-57083000

444873

1511000

3150000

996000 492000 527000 3372000 537000 5081000 0

5290643

740223

3.84

650856

89367

4535371

166667

77100000

268093

1065000

15780000

110000

2970000

2044000

4919700

53966

8.38

4535371

12.65

500000

413226

0.025

38200000

2859278

11500000

2605330

8000000

35000000

100000

0 2800000

290400

300000

P9Y1M6D

0 4000000 CRISPR THERAPEUTICS AG

4910878000

10-Q 0001674416 2013-10-28

2017-03-31

-26648000

-0.54

3746000

973000

2017 false --12-31

8642000

29000

700000

720000

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> 9. Equity-based Compensation <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company uses the straight-line attribution method to recognize stock-based compensation expense for stock options and restricted stock awards. Stock options and restricted stock awards generally vest over four years with 25% vesting on the first anniversary of service commencement and the remaining 75% vesting monthly thereafter. Effective January 1, 2017, the company adopted ASU No. 2016-09 (“ASU 2016-09”), and made an accounting policy election to account for the impact of pre-vesting forfeitures as they occur rather than applying an estimated forfeiture rate, as previously required. The following table presents stock-based compensation expense included in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,730</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">638</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,570</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">384</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Loss from equity method investment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">446</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,746</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,022</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Grant-Date Fair Value <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company estimated the fair value of each employee and non-employee stock option award on the grant date using the Black-Scholes option-pricing model based on the following assumptions: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Employees: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Weighted average expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">77.5</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Risk free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.2</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Non-employees: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Weighted average expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">81.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">n/a</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">n/a</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Risk free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">n/a</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">n/a</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The fair value of the restricted stock awards was determined based on the fair value of the common shares on the grant date. Non-employee stock options and restricted stock awards are marked-to-market at each reporting period. <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Share Based Payment Activity <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Stock Option Awards <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The following table summarizes stock option activity for employees and non-employees (intrinsic value in thousands): <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Stock Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term (years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,535,371</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.38</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,966</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">440,032</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,690</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.24</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Cancelled or forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(140,822</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.14</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,829,891</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.59</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,960</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Exercisable at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,289,490</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.27</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.6</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,568</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Vested or expected to vest at March 31, 2017 (1) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,755,902</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.51</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,417</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Represents the number of vested options at March 31, 2017 plus options expected to vest in the future.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> As of March 31, 2017, total unrecognized compensation expense related to stock options was $28.9 million which the Company expects to recognize over a remaining weighted-average period of 3.2 years. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> During the three months ended March 31, 2017 and 2016, the Company granted options to purchase 15,000 and 13,333 common shares, respectively, subject to performance-based vesting conditions. As of March 31, 2017, options to purchase 284,372 common shares subject to performance-based vesting conditions were vested, as performance conditions were achieved, and no options to purchase common shares subject to performance-based vesting conditions were deemed probable of vesting. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Restricted Stock Awards <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The following table summarizes restricted stock activity for employees and non-employees during the three months ended March 31, 2017: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Reflected as outstanding upon vesting</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Reflected as outstanding upon grant date</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Grant Date Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unvested restricted common shares as of December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">89,367</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">650,856</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">740,223</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.84</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,380</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(106,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(114,380</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.02</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unvested restricted common shares as of March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80,987</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">544,856</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">625,843</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.81</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> During the three months ended March 31, 2017, the total fair value of vested restricted common shares was $2.3 million. As of March 31, 2017, total unrecognized compensation expense related to unvested restricted common shares was $6.4 million which the Company expects to recognize over a remaining weighted-average period of 1.2 years. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company did not grant any restricted common shares subject to performance-based vesting conditions during the three months ended March 31, 2017. As of March 31, 2017, 50,000 restricted common shares subject to performance-based vesting conditions were vested. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> During the year ended December 31, 2016, the Company and Fay Corp. transferred 290,400 common shares to a founder, 268,093 of which were subject to vesting conditions with a weighted average grant date fair value of $12.65 per share. The unvested common shares are subject to repurchase by the Company upon termination of the holder’s service relationship with the Company as well as upon certain triggering events such as termination for cause, material breach of agreement and insolvency of the holder. The Company recognized expense related to these common shares in the amount of $0.2 million and $0 during the three months ended March 31, 2017 and 2016, respectively. </div>

<div> Net Loss Per Share Attributable to Common Shareholders Basic net income (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to common shareholders by the weighted-average number of common equivalent shares outstanding for the period, including any dilutive effect from outstanding stock options and warrants using the treasury stock method. The following common share equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect (in common stock equivalent shares):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Convertible preferred shares </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,301,632</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Dr. Emmanuelle Charpentier call option </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">328,017</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,829,891</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,384,908</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unvested unissued restricted common shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80,987</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">142,794</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,910,878</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27,157,351</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

Basel, Switzerland Q1

-21451000

Non-accelerated Filer

<div> 6. Commitments and Contingencies Operating Leases In March 2017, the Company entered into a sublease for a portion of one research and office facility effective April 1, 2017. The sublease term is less than the remaining term under the original lease, and as a result, the Company does not believe it has met a cease use date as it may re-enter the space following the sublease. Net payments to be received under the sublease are consistent with scheduled rent payments under the original lease. Litigation The Company licenses a U.S. patent application that is currently subject to interference proceedings declared by the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office. Following motions by the parties and other procedural matters, the PTAB concluded in February 2017 that the declared interference should be dismissed because the claim sets of the two parties were not directed to the same patentable invention in accordance with the PTAB’s two-way test for patent interferences. In April 2017, the Regents of the University of California (“California”) appealed the PTAB decision to the U.S. Court of Appeals for the Federal Circuit. In the appeal, California is seeking review and reversal of the PTAB’s February 2017 decision, which terminated the interference without determining which inventors actually invented the use of the CRISPR/Cas9 genome editing technology in eukaryotic cells. Under the Invention Management Agreement signed on December 15, 2016, the Company is obligated to share costs related to patent maintenance, defense and prosecution. The Company incurred $0.5 million and $0.6 million, for the three months ended March 31, 2017 and 2016, respectively, in shared costs. The Company recorded accrued legal costs from the cost sharing of $0.9 million and $2.8 million as of March 31, 2017 and December 31, 2016, respectively. </div>

-1000

0.013

P3Y2M12D

<div> 4. Accrued Expenses Accrued expenses consist of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">As of</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Payroll and employee-related costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,570</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,585</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Research costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">490</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">996</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Licensing fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,111</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">492</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,873</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,715</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Intellectual property costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,700</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,372</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accrued property and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,697</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,081</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">258</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,079</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,699</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,320</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

2703000

-452000

-6000

4000

<div> 3. Property and Equipment, net Property and equipment, net, consists of the following (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">As of</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Computer equipment and software </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">110</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">110</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Furniture, fixtures, and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,044</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,044</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Laboratory equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,728</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,970</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,765</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,780</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Construction work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,165</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,065</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,812</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,969</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Accumulated Depreciation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,647</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(942</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Property and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,165</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,027</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Depreciation expense was $0.7 million, and $0.1 million, for the three months ended March 31, 2017 and 2016, respectively. </div>

<div> 10. Income Taxes During the three months ended March 31, 2017 and 2016, the Company recorded an income tax provision of $0.3 million and $0.1 million, respectively, representing an effective tax rate of -1.3% and -0.9%, respectively. The income tax provision is primarily attributable to the year-to-date pre-tax income earned by the Company’s U.S. and U.K. subsidiaries. The difference in the statutory tax rate and effective tax rate is primarily a result of the jurisdictional mix of earnings and losses that are not benefited. The Company maintains a valuation allowance against certain deferred tax assets that are not more-likely-than-not realizable. As a result, the Company has not recognized a tax benefit related to the Swiss losses generated in the current periods. </div>

23447000

-21475000

-21196000

-3285000

24000

<div> Property and equipment, net, consists of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">As of</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> March 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Computer equipment and software </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">110</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">110</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Furniture, fixtures, and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,044</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,044</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Laboratory equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,728</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,970</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,765</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,780</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Construction work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,165</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,065</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,812</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,969</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accumulated Depreciation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,647</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(942</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Property and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,165</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,027</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

2515000

394000

-20744000

20000

-3648000

665000

<div> 1. Organization and Operations The Company CRISPR Therapeutics AG (“CRISPR” or the “Company”) was formed on October 28, 2013 in Basel, Switzerland. The Company was established to translate CRISPR/Cas9, a genome editing technology, into transformative gene-based medicines for the treatment of serious human diseases. The foundational intellectual property underlying the Company’s operations was licensed to the Company and its subsidiaries in April 2014. The Company devotes substantially all of its efforts to product research and development activities, initial market development and raising capital. The Company’s principal offices are located in Basel, Switzerland and its principal research operations are in Cambridge, Massachusetts. On January 23, 2014, the founders of the Company formed TRACR Hematology Limited (“TRACR”) in the United Kingdom, to further the development of the CRISPR/Cas9 technology into medicines for the treatment of blood-borne illnesses. As the Company was funding and managing TRACR’s operations in 2014, it has been consolidated by the Company from the date that the Company established a variable interest in TRACR in April 2014. In March 2015, the Company acquired 82.1% of the outstanding equity of TRACR in a share exchange transaction. Concurrent with its initial public offering (“IPO”) in October 2016, the Company acquired the outstanding non-controlling interest in TRACR, and as such, as of March 31, 2017, TRACR is a wholly-owned subsidiary of the Company. On February 7, 2014, the Company formed a wholly-owned subsidiary in the United Kingdom, CRISPR Therapeutics Limited (“CRISPR Ltd.”), and on February 16, 2015, the Company formed a wholly-owned subsidiary in the United States, CRISPR Therapeutics, Inc. (“CRISPR Inc.”), as its principal research and development operation. The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products. The Company had an accumulated deficit of $78.6 million as of March 31, 2017 and has financed its operations to date from proceeds obtained from its IPO, a series of preferred shares and convertible loan issuances, and upfront fees received under its collaboration and joint venture arrangements. The Company will require substantial additional capital to fund its research and development and ongoing operating expenses. Liquidity The Company expects its cash of $288.9 million at March 31, 2017 to be sufficient to fund its current operating plan for at least the next 24 months. Thereafter, the Company may be required to obtain additional funding. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. </div>

-446000

279000

-23412000

<div> The following table summarizes restricted stock activity for employees and non-employees during the three months ended March 31, 2017:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="58%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Reflected as outstanding upon vesting</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Reflected as outstanding upon grant date</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Grant Date Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unvested restricted common shares as of December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">89,367</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">650,856</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">740,223</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.84</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,380</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(106,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(114,380</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.02</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unvested restricted common shares as of March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80,987</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">544,856</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">625,843</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.81</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

3285000

1000

<div> 8. Share Capital The Company had 40,258,364 registered common shares as of March 31, 2017, with a par value of CHF 0.03 per share, which includes 80,987 shares of unvested unissued restricted common stock and 444,873 treasury shares which are legally outstanding but not considered outstanding for accounting purposes. Conditional Capital Reserved for Future Issuance The Company had the following conditional capital reserved for future issuance:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">As of</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom" nowrap="nowrap"> Conditional Capital </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Unvested unissued restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">166,667</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">166,667</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Outstanding stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,829,891</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,535,371</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Reserved for future issuance under stock option plans </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,996,123</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,290,643</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Shares available for bonds and similar debt instruments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,919,700</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,919,700</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Shares available for employee purchase plans </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">413,226</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">413,226</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,325,607</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,325,607</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following common share equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect (in common stock equivalent shares):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Convertible preferred shares </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">24,301,632</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Dr. Emmanuelle Charpentier call option </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">328,017</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Outstanding options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,829,891</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,384,908</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Unvested unissued restricted common shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80,987</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">142,794</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,910,878</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">27,157,351</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The Company had the following conditional capital reserved for future issuance:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="66%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">As of</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom" nowrap="nowrap"> Conditional Capital </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Unvested unissued restricted stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">166,667</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">166,667</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Outstanding stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,829,891</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,535,371</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Reserved for future issuance under stock option plans </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,996,123</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,290,643</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Shares available for bonds and similar debt instruments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,919,700</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,919,700</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Shares available for employee purchase plans </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">413,226</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">413,226</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,325,607</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,325,607</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

CRSP

14805000

20000

<div> Accrued expenses consist of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">As of</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">March 31, 2017</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Payroll and employee-related costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,570</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,585</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Research costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">490</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">996</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Licensing fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,111</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">492</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,873</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,715</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Intellectual property costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,700</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,372</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued property and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,697</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,081</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">258</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,079</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,699</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,320</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table summarizes stock option activity for employees and non-employees (intrinsic value in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Stock Options</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term (years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,535,371</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8.38</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53,966</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">440,032</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,690</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.24</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Cancelled or forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(140,822</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.14</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,829,891</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.59</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,960</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Exercisable at March 31, 2017 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,289,490</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.27</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.6</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,568</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Vested or expected to vest at March 31, 2017 (1) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,755,902</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.51</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.0</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,417</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">Represents the number of vested options at March 31, 2017 plus options expected to vest in the future.</td> </tr> </table> </div>

-21475000

3746000

39725947

1164000

<div> The Company estimated the fair value of each employee and non-employee stock option award on the grant date using the Black-Scholes option-pricing model based on the following assumptions:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2017</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2016</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Employees: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.0</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">77.5</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Risk free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.2</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.5</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr style="font-size:1pt"> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Non-employees: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Weighted average expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">81.0</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">n/a</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">n/a</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Risk free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.4</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">n/a</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">n/a</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Basis of Presentation and Use of Estimates <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP, and include the accounts of (i) the Company, and (ii) its wholly-owned subsidiaries, CRISPR Ltd., CRISPR Inc., and TRACR. All intercompany accounts and transactions have been eliminated. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The Company accounts for its 50% investment in Casebia Therapeutics LLP (“Casebia”) under the equity method of accounting. See Note 7 for further details. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, equity-based compensation expense, revenue recognition, equity method investments, and reported amounts of expenses during the period. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, research and development expenses, equity-based compensation expense, fair value of intangible assets, and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. </div> <div> Unaudited Interim Financial Information The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Annual Report. </div> -515000 2015-12-19 1136000 500000 900000

4829891000

80987000

284372

15000

50000

P1Y2M12D

2300000

114380

4.02

106000

8380

P4Y

Vest over four years with 25% vesting on the first anniversary of service commencement and the remaining 75% vesting monthly thereafter

0.75

0.25

1500000

2600000

2016-04-26

2016-01-29

0.730

0.000

0.022

P6Y

0.810

0.000

0.024

P10Y

1570000

1730000

446000

2014-02-07 2015-02-16

4690

P9Y

20.78

P8Y7M6D

140822

4.24

440032

5.14

P9Y

200000

1200000

1100000

500000

1200000

5500000

1100000

2016-02-12 6500000

To further the development of the CRISPR/Cas9 technology into medicines for the treatment of blood-borne illnesses.

2014-01-23

27157351000

44639000

-1.53

1022000

116000

6116000

-15000

100000

106000

-8446000

-11000

0.009

-8050000

476000

3286000

-146000

35000

100000

12128000

-8439000

-3000

-8366000

19668000

-4000

626000

11482000

993000

-11652000

8050000

35000000

-28000

1956000

151000

35000000

76000

-10014000

232000

2000

61929000

6012000

-8442000

1022000

5528079

172000 20000000 36372000 269000 600000

2384908000

142794000

13333

328017000

500000

600000

0.775

0.000

0.015

P6Y

P0Y

384000

638000

71400000

19000

300000

24301632000

73800000

0001674416 crsp:CasebiaTherapeuticsLlpMember 2016-01-01 2016-03-31 0001674416 us-gaap:ConvertiblePreferredStockMember 2016-01-01 2016-03-31 0001674416 crsp:BayerHealthcareLlcMember crsp:CasebiaTherapeuticsLlpMember 2016-01-01 2016-03-31 0001674416 crsp:FounderMember 2016-01-01 2016-03-31 0001674416 crsp:TRACRCharpentierLicenseAgreementMember 2016-01-01 2016-03-31 0001674416 crsp:CRISPRCharpentierLicenseAgreementMember 2016-01-01 2016-03-31 0001674416 crsp:PatentAssignmentAgreementMember 2016-01-01 2016-03-31 0001674416 crsp:FairValueOfCRISPRLicenseAcquiredMember crsp:CasebiaTherapeuticsLlpMember 2016-01-01 2016-03-31 0001674416 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001674416 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001674416 crsp:NonEmployeesMember 2016-01-01 2016-03-31 0001674416 crsp:EmployeeMember 2016-01-01 2016-03-31 0001674416 crsp:VertexPharmaceuticalsIncMember 2016-01-01 2016-03-31 0001674416 crsp:DrEmmanuelleCharpentierCallOptionMember 2016-01-01 2016-03-31 0001674416 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-01-01 2016-03-31 0001674416 crsp:UnvestedRestrictedSharesMember 2016-01-01 2016-03-31 0001674416 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001674416 2016-01-01 2016-03-31 0001674416 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2017-01-01 2017-03-31 0001674416 crsp:CasebiaTherapeuticsLlpMember 2017-01-01 2017-03-31 0001674416 crsp:BayerHealthcareLlcMember crsp:CasebiaTherapeuticsLlpMember 2017-01-01 2017-03-31 0001674416 crsp:FounderMember 2017-01-01 2017-03-31 0001674416 crsp:TRACRCharpentierLicenseAgreementMember 2017-01-01 2017-03-31 0001674416 crsp:CRISPRCharpentierLicenseAgreementMember 2017-01-01 2017-03-31 0001674416 crsp:EmployeesAndNonEmployeesMember 2017-01-01 2017-03-31 0001674416 crsp:PatentAssignmentAgreementMember 2017-01-01 2017-03-31 0001674416 crsp:CRISPRTherapeuticsIncMember country:US 2017-01-01 2017-03-31 0001674416 crsp:CRISPRTherapeuticsLimitedMember country:GB 2017-01-01 2017-03-31 0001674416 crsp:IncomeLossFromEquityMethodInvestmentMember 2017-01-01 2017-03-31 0001674416 us-gaap:ResearchAndDevelopmentExpenseMember crsp:BayerHealthcareLlcMember 2017-01-01 2017-03-31 0001674416 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0001674416 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0001674416 crsp:NonEmployeesMember 2017-01-01 2017-03-31 0001674416 crsp:EmployeeMember 2017-01-01 2017-03-31 0001674416 crsp:BayerConvertibleLoanMember 2017-01-01 2017-03-31 0001674416 crsp:VertexConvertibleLoanMember 2017-01-01 2017-03-31 0001674416 crsp:VertexPharmaceuticalsIncMember 2017-01-01 2017-03-31 0001674416 crsp:StockOptionsAndRestrictedStockAwardsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-03-31 0001674416 crsp:StockOptionsAndRestrictedStockAwardsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-01-01 2017-03-31 0001674416 crsp:StockOptionsAndRestrictedStockAwardsMember 2017-01-01 2017-03-31 0001674416 us-gaap:RestrictedStockMember crsp:OutstandingUponVestingMember 2017-01-01 2017-03-31 0001674416 us-gaap:RestrictedStockMember crsp:OutstandingUponGrantDateMember 2017-01-01 2017-03-31 0001674416 us-gaap:RestrictedStockMember 2017-01-01 2017-03-31 0001674416 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-03-31 0001674416 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-03-31 0001674416 crsp:UnvestedRestrictedSharesMember 2017-01-01 2017-03-31 0001674416 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001674416 2017-01-01 2017-03-31 0001674416 crsp:CasebiaTherapeuticsLlpMember 2016-01-01 2016-12-31 0001674416 crsp:CRISPRCharpentierLicenseAgreementMember 2016-01-01 2016-12-31 0001674416 crsp:EmployeesAndNonEmployeesMember 2016-01-01 2016-12-31 0001674416 us-gaap:ResearchAndDevelopmentExpenseMember crsp:BayerHealthcareLlcMember 2016-01-01 2016-12-31 0001674416 crsp:FayCorpAwardsMember 2016-01-01 2016-12-31 0001674416 2016-01-01 2016-12-31 0001674416 crsp:CRISPRCharpentierLicenseAgreementMember 2015-01-01 2015-12-31 0001674416 crsp:CRISPRCharpentierLicenseAgreementMember 2014-04-01 2014-04-30 0001674416 crsp:BayerConvertibleLoanMember crsp:SeriesBRedeemableConvertiblePreferredStockMember 2016-01-29 2016-01-29 0001674416 crsp:VertexConvertibleLoanMember crsp:SeriesBRedeemableConvertiblePreferredStockMember 2016-01-29 2016-01-29 0001674416 crsp:VertexConvertibleLoanMember 2015-10-26 2015-10-26 0001674416 us-gaap:EmployeeStockMember 2016-12-31 0001674416 crsp:CasebiaTherapeuticsLlpMember 2016-12-31 0001674416 crsp:BayerHealthcareLlcMember 2016-12-31 0001674416 crsp:FounderMember 2016-12-31 0001674416 crsp:EmployeesAndNonEmployeesMember 2016-12-31 0001674416 us-gaap:BondsMember 2016-12-31 0001674416 crsp:FurnitureFixturesAndOtherMember 2016-12-31 0001674416 crsp:LaboratoryEquipmentMember 2016-12-31 0001674416 crsp:ComputerEquipmentAndSoftwareMember 2016-12-31 0001674416 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001674416 us-gaap:ConstructionInProgressMember 2016-12-31 0001674416 crsp:FayCorpAwardsMember crsp:FounderMember 2016-12-31 0001674416 crsp:VertexPharmaceuticalsIncMember 2016-12-31 0001674416 crsp:UnvestedUnissuedRestrictedSharesMember 2016-12-31 0001674416 crsp:StockOptionsOutstandingMember 2016-12-31 0001674416 us-gaap:RestrictedStockMember crsp:OutstandingUponVestingMember 2016-12-31 0001674416 us-gaap:RestrictedStockMember crsp:OutstandingUponGrantDateMember 2016-12-31 0001674416 us-gaap:RestrictedStockMember 2016-12-31 0001674416 us-gaap:EmployeeStockOptionMember 2016-12-31 0001674416 2016-12-31 0001674416 crsp:BayerConvertibleLoanMember crsp:SeriesBRedeemableConvertiblePreferredStockMember 2016-01-29 0001674416 crsp:BayerConvertibleLoanMember 2016-01-29 0001674416 crsp:VertexConvertibleLoanMember crsp:SeriesBRedeemableConvertiblePreferredStockMember 2016-01-29 0001674416 2015-12-31 0001674416 us-gaap:EmployeeStockMember 2017-03-31 0001674416 crsp:CasebiaTherapeuticsLlpMember 2017-03-31 0001674416 crsp:BayerHealthcareLlcMember crsp:CasebiaTherapeuticsLlpMember 2017-03-31 0001674416 crsp:BayerHealthcareLlcMember 2017-03-31 0001674416 crsp:EmployeesAndNonEmployeesMember 2017-03-31 0001674416 us-gaap:BondsMember 2017-03-31 0001674416 crsp:FurnitureFixturesAndOtherMember 2017-03-31 0001674416 crsp:LaboratoryEquipmentMember 2017-03-31 0001674416 crsp:ComputerEquipmentAndSoftwareMember 2017-03-31 0001674416 us-gaap:LeaseholdImprovementsMember 2017-03-31 0001674416 us-gaap:ConstructionInProgressMember 2017-03-31 0001674416 crsp:UnvestedUnissuedRestrictedShareAwardsMember 2017-03-31 0001674416 crsp:ResearchAndOfficeFacilityMember 2017-03-31 0001674416 crsp:VertexPharmaceuticalsIncMember 2017-03-31 0001674416 crsp:UnvestedUnissuedRestrictedSharesMember 2017-03-31 0001674416 crsp:StockOptionsOutstandingMember 2017-03-31 0001674416 us-gaap:RestrictedStockMember crsp:OutstandingUponVestingMember 2017-03-31 0001674416 us-gaap:RestrictedStockMember crsp:OutstandingUponGrantDateMember 2017-03-31 0001674416 us-gaap:RestrictedStockMember 2017-03-31 0001674416 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-03-31 0001674416 us-gaap:EmployeeStockOptionMember 2017-03-31 0001674416 2017-03-31 0001674416 crsp:BayerHealthcareLlcMember crsp:CasebiaTherapeuticsLlpMember 2016-03-31 0001674416 2016-03-31 0001674416 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-03-24 0001674416 2017-05-08 0001674416 crsp:PatentAssignmentAgreementMember 2014-11-30 iso4217:EUR iso4217:USD shares pure iso4217:CHF shares iso4217:USD shares crsp:Sublease iso4217:CHF Including the following amounts of revenue from a related party, see Note 11: Including the following amounts of research and development expense with a related party, see Note 11:

EX-101.SCH 6 crsp-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Organization and Operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Property and Equipment, net link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Convertible Loans link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Significant Contracts link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Share Capital link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Equity-based Compensation link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Property and Equipment, net (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Share Capital (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Equity-based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Organization and Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Property and Equipment, net - Summary of Property and Equipment, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Property and Equipment, net - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Convertible Loans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Significant Contracts - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Share Capital - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Share Capital - Schedule of Conditional Capital Reserved for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Equity-based Compensation - Equity-based Compensation Expense - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Equity-based Compensation - Schedule of Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Equity-based Compensation - Fair Value of Employee and Non-employee Stock Option Award on the Grant Date Using the Black-Scholes Option-Pricing Model (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Equity-based Compensation - Summary of Stock Option Activity for Employees and Non-employees (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Equity-based Compensation - Share Based Payment Activity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Equity-based Compensation - Summary of the Company's Restricted Stock Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 crsp-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 crsp-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 crsp-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Accounts receivable, including related party amounts of $1,057 and $752 as of March 31, 2017 and December 31, 2016, respectively Accounts Receivable, Related Parties, Current Accounts receivable, related party amount, current Accrued expenses related parties current. Accrued Expenses Related Parties Current Accrued expenses related party amount, current Accrued intellectual property costs current. Accrued Intellectual Property Costs Current Intellectual property costs Accrued Liabilities, Current Accrued expenses, including related party amounts of $219 and $537 as of March 31, 2017 and December 31, 2016, respectively Total Accrued Liabilities, Current [Abstract] Accrued Liabilities, Current [Abstract] Accrued license fees current. Accrued License Fees Current Licensing fees Accrued Professional Fees, Current Professional fees Accrued property and equipment. Accrued Property And Equipment Accrued property and equipment Accrued research and development expense current. Accrued Research And Development Expense Current Research costs Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital, Common Stock Additional paid-in capital Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Reconciliation of net loss to net cash used in operating activities: Allocated Share-based Compensation Expense Equity-based compensation expense Stock-based compensation expense Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities excluded from computation of net loss per share Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Award Type [Axis] Award Type [Axis] Basis of presentation and use of estimates. Basis Of Presentation And Use Of Estimates [Policy Text Block] Basis of Presentation and Use of Estimates Bayer convertible loan. Bayer Convertible Loan [Member] Bayer Convertible Loans [Member] Bayer Healthcare LLC. Bayer Healthcare LLC [Member] Bayer Healthcare LLC [Member] Bonds [Member] Bonds and Similar Debt Instruments [Member] Business Acquisition, Percentage of Voting Interests Acquired Percentage of outstanding equity acquired Capital Expenditures Incurred but Not yet Paid Property and equipment purchases in accounts payable and accrued expenses Casebia Therapeutics LLP. Casebia Therapeutics LLP [Member] Casebia Therapeutics LLP [Member] Cash Cash Cash and Cash Equivalents, at Carrying Value Cash, end of period Cash, beginning of period Cash and Cash Equivalents, Period Increase (Decrease) (Decrease) increase in cash Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Collaborative Arrangement Disclosure [Text Block] Significant Contracts Commitments and Contingencies Commitments and contingencies (Note 6) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Capital Shares Reserved for Future Issuance Conditional capital reserved for future issuance Common Stock, Par or Stated Value Per Share Common shares, par value Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Value, Issued Common shares, CHF 0.03 par value Compensation Related Costs [Abstract] Compensation Related Costs [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Computer equipment and software. Computer Equipment And Software [Member] Computer Equipment and Software [Member] Construction in Progress [Member] Construction Work in Progress [Member] Consulting agreement annual consulting fee. Consulting Agreement Annual Consulting Fee Annual payments for consulting agreement Contingencies and commitments. Contingencies And Commitments [Line Items] Contingencies And Commitments [Line Items] Contingencies and commitments. Contingencies And Commitments [Table] Contingencies And Commitments [Table] Convertible Debt Borrowings under loan agreement Convertible Debt, Fair Value Disclosures Fair value of convertible loan Convertible Preferred Stock [Member] Convertible Preferred Shares [Member] Cost sharing expenses accrued. Cost Sharing Expenses Accrued Cost sharing expensed relating to patent maintenance, defense and prosecution, accrued Cost sharing expenses incurred. Cost Sharing Expenses Incurred Cost sharing expensed relating to patent maintenance, defense and prosecution, incurred Counterparty Name [Axis] Counterparty Name [Axis] CRISPR-Charpentier License Agreement. CRISPR Charpentier License Agreement [Member] CRISPR-Charpentier License Agreement [Member] CRISPR Therapeutics, Inc. CRISPR Therapeutics, Inc. [Member] CRISPR Therapeutics, Inc. [Member] CRISPR Therapeutics Limited. CRISPR Therapeutics Limited [Member] CRISPR Therapeutics Limited [Member] Current Fiscal Year End Date Current Fiscal Year End Date Date of formation of joint venture entity. Date of Formation of Joint Venture Entity Date of formation of joint venture entity Debt Conversion, Converted Instrument, Amount Conversion of convertible loans to Series B Preferred Shares Conversion of Vertex convertible loan and accrued interest Debt Conversion, Converted Instrument, Shares Issued Preferred shares, shares issued upon conversion Debt Conversion [Line Items] Debt Conversion [Line Items] Debt Conversion, Original Debt, Due Date of Debt Loan agreement maturity date Debt Conversion [Table] Debt Conversion [Table] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Convertible Loans Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Convertible, Carrying Amount of Equity Component Allocated to convertible loan Debt Instrument, Convertible, Conversion Price Preferred shares, conversion price per share Debt Instrument, Interest Rate, Stated Percentage Loan, accrued interest rate Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Deferred Rent Credit, Current Deferred rent Deferred Rent Credit, Noncurrent Deferred rent non-current Deferred Revenue, Noncurrent Deferred revenue, including related party amounts of $420 and $527 as of March 31, 2017 and December 31, 2016, respectively Non-current deferred revenue Deferred revenue related parties noncurrent. Deferred Revenue Related Parties Noncurrent Deferred revenue related party amount Depreciation Depreciation expense Depreciation, Depletion and Amortization Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Equity-based Compensation Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Dr. Emmanuelle Charpentier call option. Dr. Emmanuelle Charpentier Call Option [Member] Dr. Emmanuelle Charpentier Call Option [Member] Due to Related Parties Sublicense fees payable Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic and Diluted Net loss per share attributable to common shareholders-basic and diluted Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Attributable to Common Shareholders Effective Income Tax Rate Reconciliation, Percent Effective income tax rate Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations Effect of exchange rate changes on cash Employee. Employee [Member] Employee [Member] Employee-related Liabilities, Current Payroll and employee-related costs Employees and non-employees. Employees And Non Employees [Member] Employees and Non-employees [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Equity-based compensation expense not yet recognized, weighted-average service period for recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Total unrecognized compensation expenses Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Total unrecognized compensation expense Employee Stock [Member] Employee Purchase Plans [Member] Employee Stock Option [Member] Stock Option Plan [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Incorporation, Date of Incorporation Company formation date Entity Incorporation, State Country Name Company formation country name Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Investment, Name [Domain] Investment, Name [Domain] Equity Method Investment, Ownership Percentage Equity method investment, ownership percentage Equity Method Investments Equity method investment Fair value of CRISPR license acquired. Fair Value Of CRISPR License Acquired [Member] Fair Value of CRISPR License Acquired [Member] Fay Corp awards. Fay Corp Awards [Member] Fay Corp Awards [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Net Intangible assets, net Foreign Currency Transaction Gain (Loss), Unrealized Unrealized foreign currency remeasurement loss Founder. Founder [Member] Founders' [Member] Furniture, fixtures, and other. Furniture, Fixtures, and Other [Member] Furniture, Fixtures, and Other [Member] Gain (Loss) on Disposition of Property Plant Equipment Loss from disposal of property and equipment Gain (Loss) on Extinguishment of Debt Gain on extinguishment of convertible loan Gain on extinguishment of debt Gain on extinguishment of convertible loan UNITED KINGDOM United Kingdom [Member] General and Administrative Expense General and administrative General and Administrative Expense [Member] General and Administrative [Member] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net loss before income taxes Income (loss) from equity method investment. Income Loss From Equity Method Investment [Member] Loss from Equity Method Investment [Member] Income (Loss) from Equity Method Investments Loss from equity method investment Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Tax Expense (Benefit) Income tax provision Provision for income taxes Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Accounts Receivable Accounts receivable Increase decrease in deferred rent payable. Increase Decrease In Deferred Rent Payable Deferred rent Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Operating Capital [Abstract] Changes in: Increase (Decrease) in Other Operating Liabilities Other liabilities, net Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Restricted Cash Restricted cash Interest Expense Interest expense Interest Income (Expense), Nonoperating, Net Interest expense Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Joint venture agreement date. Joint Venture Agreement Date Date of joint venture agreement Laboratory equipment. Laboratory Equipment [Member] Laboratory Equipment [Member] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Leasehold Improvements [Member] Leasehold Improvements [Member] Legal Entity [Axis] Legal Entity [Axis] Liabilities Total liabilities Liabilities and Equity Total liabilities and shareholders' equity Liabilities and Equity [Abstract] Liabilities and shareholders' equity Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: License and Services Revenue Revenue from collaboration agreement License Costs Sublicense fees recorded Upfront fees paid for license Long-term Line of Credit Borrowings under loan agreement Line of Credit Facility, Interest Rate During Period Loan, accrued interest rate Milestone payment amount. Milestone Payment Amount Clinical milestone payment payable Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities: Net Income (Loss) Attributable to Parent Net loss attributable to common shareholders Net Income (Loss) Attributable to Noncontrolling Interest Loss attributable to noncontrolling interest Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Reconciliation of net loss to net loss attributable to common shareholders: New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Noncash contribution of intellectual property to equity method investee. Noncash Contribution Of Intellectual Property To Equity Method Investee Noncash contribution of intellectual property to Casebia LLP Noncash Investing and Financing Items [Abstract] Supplemental disclosure of non-cash investing and financing activities Noncontrolling Interest in Net Income (Loss) Joint Venture Partners, Nonredeemable Net loss of joint venture Non employees. Non Employees [Member] Non-Employees [Member] Nonoperating Income (Expense) Total other (expense) income, net Nonoperating Income (Expense) [Abstract] Other (expense) income: Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Loss from operations Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Organization and operations. Organization and operations [Line Items] Organization and operations [Line Items] Organization and operations. Organization and Operations [Table] Organization and Operations [Table] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] EX-101.PRE 10 crsp-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 08, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	CRSP
Entity Registrant Name	CRISPR THERAPEUTICS AG
Entity Central Index Key	0001674416
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		39,997,525

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 288,872	$ 315,520
Accounts receivable, including related party amounts of $1,057 and $752 as of March 31, 2017 and December 31, 2016, respectively	5,672	3,157
Prepaid expenses and other current assets including related party amounts of $577 and $0 as of March 31, 2017 and December 31, 2016, respectively	1,918	1,511
Total current assets	296,462	320,188
Property and equipment, net	22,165	21,027
Intangible assets, net	385	399
Restricted cash	3,151	3,150
Other non-current assets	183	198
Total assets	322,346	344,962
Current liabilities:
Accounts payable	3,937	4,569
Accrued expenses, including related party amounts of $219 and $537 as of March 31, 2017 and December 31, 2016, respectively	11,699	16,320
Accrued tax liabilities	190	23
Deferred rent	1,027	1,027
Other current liabilities	62	59
Total current liabilities	16,915	21,998
Deferred revenue, including related party amounts of $420 and $527 as of March 31, 2017 and December 31, 2016, respectively	78,311	77,646
Deferred rent non-current	11,768	12,283
Other non-current liabilities	177	189
Total liabilities	107,171	112,116
Commitments and contingencies (Note 6)
Shareholders' equity:
Common shares, CHF 0.03 par value	1,216	1,216
Treasury shares, at cost, 444,873 shares at March 31, 2017 and December 31, 2016	0	0
Additional paid-in capital	292,519	288,739
Accumulated deficit	(78,558)	(57,083)
Accumulated other comprehensive loss	(2)	(26)
Total shareholders' equity	215,175	232,846
Total liabilities and shareholders' equity	$ 322,346	$ 344,962

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) $ in Thousands	Mar. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares
Statement of Financial Position [Abstract]
Accounts receivable, related party amount, current	$ 1,057	$ 752
Prepaid expenses and other current assets, related party amount	577	0
Accrued expenses related party amount, current	219	537
Deferred revenue related party amount	$ 420	$ 527
Treasury stock, shares \| shares	444,873	444,873

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Income Statement [Abstract]

Collaboration revenue

^[1]

$ 2,703

$ 476

Operating expenses:

Research and development

^[2]

14,805

6,012

General and administrative

8,642

6,116

Total operating expenses

23,447

12,128

Loss from operations

(20,744)

(11,652)

Other (expense) income:

Interest expense

(8,050)

Loss from equity method investment

(446)

Gain on extinguishment of convertible loan

11,482

Other expense, net

(6)

(146)

Total other (expense) income, net

(452)

3,286

Net loss before income taxes

(21,196)

(8,366)

Provision for income taxes

(279)

(76)

Net loss

(21,475)

(8,442)

Foreign currency translation adjustment

(4)

Comprehensive loss

(21,451)

(8,446)

Reconciliation of net loss to net loss attributable to common shareholders:

Net loss

(21,475)

(8,442)

Loss attributable to noncontrolling interest

Net loss attributable to common shareholders

$ (21,475)

$ (8,439)

Net loss per share attributable to common shareholders-basic and diluted

$ (0.54)

$ (1.53)

Weighted-average common shares outstanding used in net loss per share attributable to common shareholders-basic and diluted

39,725,947

5,528,079

[1]	Including the following amounts of revenue from a related party, see Note 11:
[2]	Including the following amounts of research and development expense with a related party, see Note 11:

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenue from related party	$ 1,164
Research and development expense with a related party	$ 1,136	$ 269

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net loss	$ (21,475)	$ (8,442)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	720	106
Equity-based compensation	3,746	1,022
Non-cash interest expense		8,050
Loss from disposal of property and equipment		28
Unrealized foreign currency remeasurement loss	1	11
Gain on extinguishment of convertible loan		(11,482)
Changes in:
Restricted cash	(1)	(2)
Accounts receivable	(2,515)	(626)
Prepaid expenses and other assets	(394)	(993)
Accounts payable and accrued expenses	(3,648)	1,956
Deferred revenue	665	151
Deferred rent	(515)	172
Other liabilities, net	4	35
Net cash used in operating activities	(23,412)	(10,014)
Investing activities:
Purchase of property and equipment	(3,285)	(232)
Proceeds from contribution of intellectual property to equity method investee		20,000
Cash investment in equity method investee		(100)
Net cash (used in) provided by investing activities	(3,285)	19,668
Financing activities:
Proceeds from exercise of options	20
Proceeds from issuance of convertible loans		35,000
Net cash provided by financing activities	20	35,000
Effect of exchange rate changes on cash	29	(15)
(Decrease) increase in cash	(26,648)	44,639
Cash, beginning of period	315,520	155,961
Cash, end of period	288,872	200,600
Supplemental disclosure of non-cash investing and financing activities
Property and equipment purchases in accounts payable and accrued expenses	$ 973	116
Conversion of Vertex convertible loan and accrued interest		61,929
Noncash contribution of intellectual property to Casebia LLP		$ 36,372

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Operations	3 Months Ended
Organization and Operations	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Operations	1. Organization and Operations *The Company* CRISPR Therapeutics AG (“CRISPR” or the “Company”) was formed on October 28, 2013 in Basel, Switzerland. The Company was established to translate CRISPR/Cas9, a genome editing technology, into transformative gene-based medicines for the treatment of serious human diseases. The foundational intellectual property underlying the Company’s operations was licensed to the Company and its subsidiaries in April 2014. The Company devotes substantially all of its efforts to product research and development activities, initial market development and raising capital. The Company’s principal offices are located in Basel, Switzerland and its principal research operations are in Cambridge, Massachusetts. On January 23, 2014, the founders of the Company formed TRACR Hematology Limited (“TRACR”) in the United Kingdom, to further the development of the CRISPR/Cas9 technology into medicines for the treatment of blood-borne illnesses. As the Company was funding and managing TRACR’s operations in 2014, it has been consolidated by the Company from the date that the Company established a variable interest in TRACR in April 2014. In March 2015, the Company acquired 82.1% of the outstanding equity of TRACR in a share exchange transaction. Concurrent with its initial public offering (“IPO”) in October 2016, the Company acquired the outstanding non-controlling interest in TRACR, and as such, as of March 31, 2017, TRACR is a wholly-owned subsidiary of the Company. On February 7, 2014, the Company formed a wholly-owned subsidiary in the United Kingdom, CRISPR Therapeutics Limited (“CRISPR Ltd.”), and on February 16, 2015, the Company formed a wholly-owned subsidiary in the United States, CRISPR Therapeutics, Inc. (“CRISPR Inc.”), as its principal research and development operation. The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products. The Company had an accumulated deficit of $78.6 million as of March 31, 2017 and has financed its operations to date from proceeds obtained from its IPO, a series of preferred shares and convertible loan issuances, and upfront fees received under its collaboration and joint venture arrangements. The Company will require substantial additional capital to fund its research and development and ongoing operating expenses. *Liquidity* The Company expects its cash of $288.9 million at March 31, 2017 to be sufficient to fund its current operating plan for at least the next 24 months. Thereafter, the Company may be required to obtain additional funding. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Unaudited Interim Financial Information

Basis of Presentation and Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, equity-based compensation expense, revenue recognition, equity method investments, and reported amounts of expenses during the period. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, research and development expenses, equity-based compensation expense, fair value of intangible assets, and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Net Loss Per Share Attributable to Common Shareholders


	Three Months Ended March 31,
	2017		2016
Convertible preferred shares		—		24,301,632
Dr. Emmanuelle Charpentier call option		—		328,017
Outstanding options		4,829,891		2,384,908
Unvested unissued restricted common shares		80,987		142,794

Total		4,910,878		27,157,351

Recent Accounting Pronouncements

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) (“ASU 2017-01”). ASU 2017-01 clarifies whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The purpose of the guidance is to narrow the definition of a business at it relates recording transactions as business acquisitions or asset acquisitions. The guidance is effective in annual periods beginning after December 15, 2017, including interim periods within those years, with early adoption permitted under certain circumstances. The Company does not expect any additional impact on its financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment, net

3. Property and Equipment, net

Property and equipment, net, consists of the following (in thousands):


	As of
	March 31,			December 31,
	2017			2016
Computer equipment and software	$	110		$	110
Furniture, fixtures, and other		2,044			2,044
Laboratory equipment		4,728			2,970
Leasehold improvements		15,765			15,780
Construction work in process		1,165			1,065

		23,812			21,969
Accumulated Depreciation		(1,647	)		(942	)

Property and equipment, net	$	22,165		$	21,027

Depreciation expense was $0.7 million, and $0.1 million, for the three months ended March 31, 2017 and 2016, respectively.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Accrued Expenses

4. Accrued Expenses

Accrued expenses consist of the following (in thousands):


	As of
	March 31, 2017		December 31, 2016
Payroll and employee-related costs	$	1,570	$	2,585
Research costs		490		996
Licensing fees		1,111		492
Professional fees		1,873		2,715
Intellectual property costs		1,700		3,372
Accrued property and equipment		4,697		5,081
Other		258		1,079

Total	$	11,699	$	16,320

XML 21 R11.htm IDEA: XBRL DOCUMENT

Convertible Loans	3 Months Ended
Convertible Loans	Mar. 31, 2017
Debt Disclosure [Abstract]
Convertible Loans	5. Convertible Loans *2015 Convertible Loan Agreement with Vertex and certain existing shareholders* On October 26, 2015, the Company entered into a convertible loan agreement with Vertex Pharmaceuticals Incorporated (“Vertex”) and certain existing shareholders (the “Vertex Convertible Loan”) under which the Company borrowed $38.2 million. The Vertex Convertible Loan accrued interest at 2.5% per annum and had an initial maturity date of April 26, 2016 subject to acceleration upon the occurrence of certain conditions. The Vertex Convertible Loan included various embedded conversion, redemption and other features, none of which required separate accounting from the host instrument under ASC Topic 815: Derivatives and Hedging (“ASC 815”). The conversion terms, redemption terms, and other features of the Vertex Convertible Loan are included in the Annual Report. *Convertible Loan with Bayer Global Investments B.V.* On January 29, 2016, concurrent with the execution of an agreement to establish a Joint Venture (“JV”) with Bayer HealthCare LLC (“Bayer HealthCare”), the Company entered into a Convertible Loan Agreement (the “Bayer Convertible Loan”) with Bayer Global Investments B.V. (“Bayer BV”) under which the Company borrowed $35.0 million. The Bayer Convertible Loan accrued interest at 2.0% per annum and matured on January 29, 2016. The Bayer Convertible Loan included various embedded conversion, redemption and other features, none of which required separate accounting from the host instrument under ASC 815. The conversion terms, redemption terms, and other features of the Bayer Convertible Loan are included in the Annual Report. *Conversion of Convertible Loans to Series B Preferred Shares* On January 29, 2016, concurrent with the issuance of the Bayer Convertible Loan, all of the outstanding principal under the $35.0 million Bayer Convertible Loan automatically converted into 2,605,330 Series B Redeemable Convertible Preferred Shares (“Series B Preferred Shares”) at $13.43 per share. The Company determined the fair value of the Bayer Convertible Loan to be $24.5 million based on the fair value of the underlying Series B Preferred Shares that were exchanged as part of the immediate conversion. As the Bayer Convertible Loan was executed in contemplation of the joint venture agreement with Bayer, the Company evaluated the Bayer Convertible Loan as part of one multiple-element arrangement and, using a relative fair value allocation method, allocated $27.0 million of aggregate arrangement consideration to the Bayer Convertible Loan upon issuance. Upon conversion, the Company accreted the Bayer Convertible Loan to its face value of $35.0 million through a charge to interest expense of $8.0 million and converted the $35.0 million to Series B Preferred Shares under the conversion model. The receipt of $35.0 million in proceeds under the Bayer Convertible Loan in exchange for equity securities, combined with the $38.2 million in proceeds from Vertex Convertible Loan, triggered an automatic conversion provision of the Vertex Convertible Loan Agreement. Accordingly, on January 29, 2016, the Vertex Convertible Loan, including loans from existing shareholders, plus accrued interest also converted into 2,859,278 of Series B Preferred Shares at $13.43 per share. The Company determined the fair value of the Vertex Convertible Loan to be $26.9 million based on the fair value of the underlying Series B Preferred Shares that were exchanged as part of the conversion. Upon extinguishment, the Company recorded a gain on extinguishment of $11.5 million for the difference between the carrying value of the debt and the fair value of the Series B Preferred Shares issued to settle the debt under the general extinguishment model.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies *Operating Leases* In March 2017, the Company entered into a sublease for a portion of one research and office facility effective April 1, 2017. The sublease term is less than the remaining term under the original lease, and as a result, the Company does not believe it has met a cease use date as it may re-enter the space following the sublease. Net payments to be received under the sublease are consistent with scheduled rent payments under the original lease. *Litigation* The Company licenses a U.S. patent application that is currently subject to interference proceedings declared by the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office. Following motions by the parties and other procedural matters, the PTAB concluded in February 2017 that the declared interference should be dismissed because the claim sets of the two parties were not directed to the same patentable invention in accordance with the PTAB’s two-way test for patent interferences. In April 2017, the Regents of the University of California (“California”) appealed the PTAB decision to the U.S. Court of Appeals for the Federal Circuit. In the appeal, California is seeking review and reversal of the PTAB’s February 2017 decision, which terminated the interference without determining which inventors actually invented the use of the CRISPR/Cas9 genome editing technology in eukaryotic cells. Under the Invention Management Agreement signed on December 15, 2016, the Company is obligated to share costs related to patent maintenance, defense and prosecution. The Company incurred $0.5 million and $0.6 million, for the three months ended March 31, 2017 and 2016, respectively, in shared costs. The Company recorded accrued legal costs from the cost sharing of $0.9 million and $2.8 million as of March 31, 2017 and December 31, 2016, respectively.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Significant Contracts	3 Months Ended
Significant Contracts	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Significant Contracts	7. Significant Contracts *Intellectual Property Agreements* CRISPR Therapeutics AG—Charpentier License Agreement In April 2014, the Company entered into a technology license agreement with Dr. Charpentier pursuant to which the Company licensed certain intellectual property rights under joint ownership from Dr. Charpentier to develop and commercialize products for the treatment or prevention of human diseases other than hemoglobinopathies (“CRISPR—Charpentier License Agreement”). In consideration for the granting of the license, the Company paid Dr. Charpentier an upfront fee of CHF 0.1 million ($0.1 million), and agreed to pay an immaterial annual license maintenance fee if Dr. Charpentier is not otherwise engaged in a service arrangement with the Company. During the years ended December 31, 2016 and 2015, and three months ended March 31, 2017 and 2016, Dr. Charpentier has been in a consulting arrangement with the Company, as such, no annual payments have been made under this provision. Dr. Charpentier is entitled to receive nominal clinical milestone payments. The Company is also obligated to pay Dr. Charpentier a low single digit percentage of sublicensing payments received under any sublicense agreement with a third party. In addition, the Company is also obligated to pay to Dr. Charpentier a low single-digit percentage royalty based on annual net sales of licensed products and licensed services by the Company and its affiliates and sublicensees. During the three months ended March 31, 2017 and 2016, the Company recorded $0 and $0.3 million, respectively, of sublicensing fees due to Dr. Charpentier. These expenses were under the terms of the CRISPR—Charpentier License Agreement that was triggered by the execution of the Bayer Agreement (“Bayer Agreement”). TRACR Hematology Limited—Charpentier License Agreement In April 2014, TRACR entered into a technology license agreement (“TRACR—Charpentier License Agreement”) with Dr. Charpentier pursuant to which TRACR licensed certain intellectual property rights under joint ownership from Dr. Charpentier to develop and commercialize products for the treatment or prevention of human diseases related to hemoglobinopathies. In consideration for the granting of the license, Dr. Charpentier is entitled to receive nominal clinical milestone payments. TRACR is also obligated to pay Dr. Charpentier a low single digit percentage of sublicensing payments received under any sublicense agreement with a third party. In addition, TRACR is obligated to pay to Dr. Charpentier low single digit percentage royalties based on annual net sales of licensed products and licensed services by the Company and its affiliates and sublicensees. During the three months ended March 31, 2017 and 2016, the Company did not record any sublicensing fees due to Dr. Charpentier under the terms of the TRACR—Charpentier License Agreement. Patent Assignment Agreement In November 2014, the Company entered into a patent assignment agreement (“Patent Assignment Agreement”) with Dr. Charpentier, Dr. Ines Fonfara, and the University of Vienna (collectively, the “Assignors”), pursuant to which the Company received from the assignors all rights, title and interest in and to certain patent rights claimed in the U.S. Patent Application No.61/905,835. In consideration for the assignment of such rights, the Assignors are entitled to receive clinical milestone payments totaling up to €0.3 million (approximately $0.4 million) in the aggregate for the first human therapeutic product. The Company is also obligated to pay to the Assignors low single digit royalties based on annual net sales of certain products and services by the Company and its affiliates and sublicensees. During the three months ended March 31, 2017 and 2016, the Company recorded $0 and $19 thousand, respectively, of sublicensing fees due to the Assignors under the terms of the Patent Assignment Agreement that was triggered under the Vertex collaboration agreement and by the execution of the Bayer Agreement. *Collaboration Agreement with Vertex Pharmaceuticals, Incorporated* On October 26, 2015, the Company entered into a strategic collaboration, option, and license agreement (“Collaboration Agreement”) with Vertex, focused on the use of CRISPR’s gene editing technology, CRISPR/Cas9, to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. During the three months ended March 31, 2017 and 2016, the Company recognized $1.5 million and $0.5 million of revenue related to the collaboration with Vertex. Research and development expense incurred by the Company in relation to its performance under the Collaboration Agreement for the three months ended March 31, 2017 and 2016 was $2.6 million and $0.6 million, respectively. As of March 31, 2017 and December 31, 2016, there was $77.9 million and $77.1 million of non-current deferred revenue related to the Company’s collaboration with Vertex, respectively. *Joint Venture with Bayer Healthcare LLC* On December 19, 2015, the Company entered into an agreement with Bayer HealthCare LLC to establish the JV to discover, develop and commercialize new therapeutics to cure blood disorders, blindness, and congenital heart disease. On February 12, 2016, the Company and Bayer HealthCare completed the formation of the joint venture entity, Casebia. CRISPR contributed its proprietary CRISPR/Cas9 gene editing technology and intellectual property for selected disease indications and Bayer HealthCare contributed its protein engineering expertise and relevant disease know-how. At March 31, 2017 and December 31, 2016, the Company’s equity method investment in Casebia was zero. During the three months ended March 31, 2017 and 2016, the Company recognized $1.2 million and $0 of revenue, respectively, related to the collaboration with Casebia. During the three months ended March 31, 2017 and 2016, the Company recognized $1.1 million and $0 of research and development expense, respectively, in relation to its performance under the agreement. During the three months ended March 31, 2017 and 2016, the Company recognized $0.5 million and $0, respectively, of stock-based compensation expense related to Casebia employees. Non-current deferred revenue related to the Company’s collaboration with Casebia was $0.4 million and $0.5 million as of March 31, 2017 and December 31, 2016, respectively. Unrecognized equity method losses in excess of the Company’s equity investment in Casebia was $6.5 million and $4.0 million as of March 31, 2017 and December 31, 2016, respectively. Total operating expenses, and net loss of Casebia for the three months ended March 31, 2017 was $5.5 million. During the three months ended March 31, 2016, total operating expenses and net loss of Casebia was $73.8 million which included research and development expenses of $71.4 million for the fair value of the CRISPR license acquired.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Share Capital

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Share Capital

8. Share Capital

Conditional Capital Reserved for Future Issuance

The Company had the following conditional capital reserved for future issuance:


	As of
Conditional Capital	March 31, 2017		December 31, 2016
Unvested unissued restricted stock		166,667		166,667
Outstanding stock options		4,829,891		4,535,371
Reserved for future issuance under stock option plans		4,996,123		5,290,643
Shares available for bonds and similar debt instruments		4,919,700		4,919,700
Shares available for employee purchase plans		413,226		413,226

Total		15,325,607		15,325,607

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Equity-based Compensation

3 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity-based Compensation

9. Equity-based Compensation


	Three Months Ended March 31,
	2017		2016
Research and development	$	1,730	$	638
General and administrative		1,570		384
Loss from equity method investment		446		—

Total	$	3,746	$	1,022

Grant-Date Fair Value

The Company estimated the fair value of each employee and non-employee stock option award on the grant date using the Black-Scholes option-pricing model based on the following assumptions:


	Three Months Ended March 31,
	2017			2016
Employees:
Weighted average expected volatility		73.0	%		77.5	%
Expected term (in years)		6.0			6.0
Risk free interest rate		2.2	%		1.5	%
Expected dividend yield		0.0	%		0.0	%

Non-employees:
Weighted average expected volatility		81.0	%		n/a
Expected term (in years)		10.0			n/a
Risk free interest rate		2.4	%		n/a
Expected dividend yield		0.0	%		n/a

Share Based Payment Activity

Stock Option Awards

The following table summarizes stock option activity for employees and non-employees (intrinsic value in thousands):


	Stock Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2016		4,535,371		$	8.38		9.1	$	53,966

Granted		440,032		$	20.78
Exercised		(4,690	)	$	4.24
Cancelled or forfeited		(140,822	)	$	5.14

Outstanding at March 31, 2017		4,829,891		$	9.59		9.0	$	58,960

Exercisable at March 31, 2017		1,289,490		$	4.27		8.6	$	22,568

Vested or expected to vest at March 31, 2017 (1)		4,755,902		$	9.51		9.0	$	58,417

(1)	Represents the number of vested options at March 31, 2017 plus options expected to vest in the future.

As of March 31, 2017, total unrecognized compensation expense related to stock options was $28.9 million which the Company expects to recognize over a remaining weighted-average period of 3.2 years.

Restricted Stock Awards

The following table summarizes restricted stock activity for employees and non-employees during the three months ended March 31, 2017:


	Reflected as outstanding upon vesting			Reflected as outstanding upon grant date			Total			Weighted- Average Grant Date Fair Value
Unvested restricted common shares as of December 31, 2016		89,367			650,856			740,223		$	3.84

Vested		(8,380	)		(106,000	)		(114,380	)		4.02

Unvested restricted common shares as of March 31, 2017		80,987			544,856			625,843		$	3.81

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes During the three months ended March 31, 2017 and 2016, the Company recorded an income tax provision of $0.3 million and $0.1 million, respectively, representing an effective tax rate of -1.3% and -0.9%, respectively. The income tax provision is primarily attributable to the year-to-date pre-tax income earned by the Company’s U.S. and U.K. subsidiaries. The difference in the statutory tax rate and effective tax rate is primarily a result of the jurisdictional mix of earnings and losses that are not benefited. The Company maintains a valuation allowance against certain deferred tax assets that are not more-likely-than-not realizable. As a result, the Company has not recognized a tax benefit related to the Swiss losses generated in the current periods.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions The Company is a party to intellectual property license agreements with Dr. Charpentier. As of March 31, 2017 and December 31, 2016, the Company owed Dr. Charpentier approximately $0.2 million and $0.5 million, respectively, of sublicense fees primarily related to the Bayer Agreement. During the three months ended March 31, 2017 and 2016, the Company recorded sublicensing fees of $0 and $0.3 million, respectively, due to Dr. Charpentier in research and development expense related to the Bayer Agreement. The Company is a party to the JV with Bayer HealthCare. During the three months ended March 31, 2017 and 2016, the Company recognized revenue of $1.2 million and $0, respectively, related to the collaboration with Casebia. During the three months ended March 31, 2017, and 2016, the Company recognized $1.1 million and $0 of research and development expense, respectively, related to the performance of services for Casebia. As of March 31, 2017 and December 31, 2016, the Company recorded accounts receivable of $1.1 million and $0.8 million, respectively, other current assets of $0.6 million and $0, respectively, and deferred revenue of $0.4 million and $0.5 million, respectively, related to Casebia.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Unaudited Interim Financial Information

Unaudited Interim Financial Information

Basis of Presentation and Use of Estimates

Basis of Presentation and Use of Estimates

Net Loss Per Share Attributable to Common Shareholders

Net Loss Per Share Attributable to Common Shareholders


	Three Months Ended March 31,
	2017		2016
Convertible preferred shares		—		24,301,632
Dr. Emmanuelle Charpentier call option		—		328,017
Outstanding options		4,829,891		2,384,908
Unvested unissued restricted common shares		80,987		142,794

Total		4,910,878		27,157,351

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share


	Three Months Ended March 31,
	2017		2016
Convertible preferred shares		—		24,301,632
Dr. Emmanuelle Charpentier call option		—		328,017
Outstanding options		4,829,891		2,384,908
Unvested unissued restricted common shares		80,987		142,794

Total		4,910,878		27,157,351

XML 30 R20.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Summary of Property and Equipment, Net

Property and equipment, net, consists of the following (in thousands):


	As of
	March 31,			December 31,
	2017			2016
Computer equipment and software	$	110		$	110
Furniture, fixtures, and other		2,044			2,044
Laboratory equipment		4,728			2,970
Leasehold improvements		15,765			15,780
Construction work in process		1,165			1,065

		23,812			21,969
Accumulated Depreciation		(1,647	)		(942	)

Property and equipment, net	$	22,165		$	21,027

XML 31 R21.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued expenses consist of the following (in thousands):


	As of
	March 31, 2017		December 31, 2016
Payroll and employee-related costs	$	1,570	$	2,585
Research costs		490		996
Licensing fees		1,111		492
Professional fees		1,873		2,715
Intellectual property costs		1,700		3,372
Accrued property and equipment		4,697		5,081
Other		258		1,079

Total	$	11,699	$	16,320

XML 32 R22.htm IDEA: XBRL DOCUMENT

Share Capital (Tables)

3 Months Ended

Mar. 31, 2017

Equity [Abstract]

Schedule of Conditional Capital Reserved for Future Issuance

The Company had the following conditional capital reserved for future issuance:


	As of
Conditional Capital	March 31, 2017		December 31, 2016
Unvested unissued restricted stock		166,667		166,667
Outstanding stock options		4,829,891		4,535,371
Reserved for future issuance under stock option plans		4,996,123		5,290,643
Shares available for bonds and similar debt instruments		4,919,700		4,919,700
Shares available for employee purchase plans		413,226		413,226

Total		15,325,607		15,325,607

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

+ Details

XML 33 R23.htm IDEA: XBRL DOCUMENT

Equity-based Compensation (Tables)

3 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-Based Compensation Expense


	Three Months Ended March 31,
	2017		2016
Research and development	$	1,730	$	638
General and administrative		1,570		384
Loss from equity method investment		446		—

Total	$	3,746	$	1,022

Fair Value of Employee and Non-employee Stock Option Award on the Grant Date Using the Black-Scholes Option-Pricing Model

The Company estimated the fair value of each employee and non-employee stock option award on the grant date using the Black-Scholes option-pricing model based on the following assumptions:


	Three Months Ended March 31,
	2017			2016
Employees:
Weighted average expected volatility		73.0	%		77.5	%
Expected term (in years)		6.0			6.0
Risk free interest rate		2.2	%		1.5	%
Expected dividend yield		0.0	%		0.0	%

Non-employees:
Weighted average expected volatility		81.0	%		n/a
Expected term (in years)		10.0			n/a
Risk free interest rate		2.4	%		n/a
Expected dividend yield		0.0	%		n/a

Summary of Stock Option Activity for Employees and Non-employees

The following table summarizes stock option activity for employees and non-employees (intrinsic value in thousands):


	Stock Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2016		4,535,371		$	8.38		9.1	$	53,966

Granted		440,032		$	20.78
Exercised		(4,690	)	$	4.24
Cancelled or forfeited		(140,822	)	$	5.14

Outstanding at March 31, 2017		4,829,891		$	9.59		9.0	$	58,960

Exercisable at March 31, 2017		1,289,490		$	4.27		8.6	$	22,568

Vested or expected to vest at March 31, 2017 (1)		4,755,902		$	9.51		9.0	$	58,417

(1)	Represents the number of vested options at March 31, 2017 plus options expected to vest in the future.

Summary of the Company's Restricted Stock Activity

The following table summarizes restricted stock activity for employees and non-employees during the three months ended March 31, 2017:


	Reflected as outstanding upon vesting			Reflected as outstanding upon grant date			Total			Weighted- Average Grant Date Fair Value
Unvested restricted common shares as of December 31, 2016		89,367			650,856			740,223		$	3.84

Vested		(8,380	)		(106,000	)		(114,380	)		4.02

Unvested restricted common shares as of March 31, 2017		80,987			544,856			625,843		$	3.81

XML 34 R24.htm IDEA: XBRL DOCUMENT

Organization and Operations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 24, 2015
Organization and operations [Line Items]
Company formation date	Oct. 28, 2013
Company formation country name	Basel, Switzerland
Accumulated deficit	$ (78,558)	$ (57,083)
Cash	$ 288,872	$ 315,520
CRISPR Therapeutics Limited [Member] \| United Kingdom [Member]
Organization and operations [Line Items]
Subsidiary formation date	Feb. 07, 2014
CRISPR Therapeutics, Inc. [Member] \| United States [Member]
Organization and operations [Line Items]
Subsidiary formation date	Feb. 16, 2015
TRACR Hematology Limited [Member]
Organization and operations [Line Items]
Formation date, VIE	Jan. 23, 2014
Relationship nature and extent of involvement in VIE	On January 23, 2014, the founders of the Company formed TRACR Hematology Limited (“TRACR”) in the United Kingdom, to further the development of the CRISPR/Cas9 technology into medicines for the treatment of blood-borne illnesses. As the Company was funding and managing TRACR’s operations in 2014, it has been consolidated by the Company from the date that the Company established a variable interest in TRACR in April 2014. In March 2015, the Company acquired 82.1% of the outstanding equity of TRACR in a share exchange transaction. Concurrent with its initial public offering (“IPO”) in October 2016, the Company acquired the outstanding non-controlling interest in TRACR, and as such, as of March 31, 2017, TRACR is a wholly-owned subsidiary of the Company.
Purpose of VIE	To further the development of the CRISPR/Cas9 technology into medicines for the treatment of blood-borne illnesses.
Percentage of outstanding equity acquired			82.10%

XML 35 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail)	Mar. 31, 2017
Casebia Therapeutics LLP [Member]
Summary Of Significant Accounting Policies [Line Items]
Equity method investment, ownership percentage	50.00%

XML 36 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of net loss per share	4,910,878	27,157,351
Convertible Preferred Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of net loss per share		24,301,632
Dr. Emmanuelle Charpentier Call Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of net loss per share		328,017
Stock Option Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of net loss per share	4,829,891	2,384,908
Unvested Unissued Restricted Common Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of net loss per share	80,987	142,794

XML 37 R27.htm IDEA: XBRL DOCUMENT

Property and Equipment, net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 23,812	$ 21,969
Accumulated Depreciation	(1,647)	(942)
Property and equipment, net	22,165	21,027
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	110	110
Furniture, Fixtures, and Other [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	2,044	2,044
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	4,728	2,970
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	15,765	15,780
Construction Work in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 1,165	$ 1,065

XML 38 R28.htm IDEA: XBRL DOCUMENT

Property and Equipment, net - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0.7	$ 0.1

XML 39 R29.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Payroll and employee-related costs	$ 1,570	$ 2,585
Research costs	490	996
Licensing fees	1,111	492
Professional fees	1,873	2,715
Intellectual property costs	1,700	3,372
Accrued property and equipment	4,697	5,081
Other	258	1,079
Total	$ 11,699	$ 16,320

XML 40 R30.htm IDEA: XBRL DOCUMENT

Convertible Loans - Additional Information (Detail) - USD ($)			3 Months Ended
	Jan. 29, 2016	Oct. 26, 2015	Mar. 31, 2017	Mar. 31, 2016
Debt Conversion [Line Items]
Borrowings under loan agreement				$ 35,000,000
Conversion of convertible loans to Series B Preferred Shares				61,929,000
Gain on extinguishment of debt				$ 11,482,000
Bayer Convertible Loans [Member]
Debt Conversion [Line Items]
Loan agreement maturity date			Jan. 29, 2016
Borrowings under loan agreement	$ 35,000,000
Loan, accrued interest rate	2.00%
Borrowings under loan agreement	$ 35,000,000
Vertex Convertible Loans [Member]
Debt Conversion [Line Items]
Borrowings under loan agreement		$ 38,200,000
Loan, accrued interest rate		2.50%
Loan agreement maturity date			Apr. 26, 2016
Series B Redeemable Convertible Preferred Shares [Member] \| Bayer Convertible Loans [Member]
Debt Conversion [Line Items]
Preferred shares, shares issued upon conversion	2,605,330
Preferred shares, conversion price per share	$ 13.43
Fair value of convertible loan	$ 24,500,000
Allocated to convertible loan	27,000,000
Interest expense	8,000,000
Conversion of convertible loans to Series B Preferred Shares	$ 35,000,000
Series B Redeemable Convertible Preferred Shares [Member] \| Vertex Convertible Loans [Member]
Debt Conversion [Line Items]
Preferred shares, shares issued upon conversion	2,859,278
Preferred shares, conversion price per share	$ 13.43
Fair value of convertible loan	$ 26,900,000
Gain on extinguishment of debt	$ 11,500,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2017 USD ($) Sublease	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)
Contingencies And Commitments [Line Items]
Cost sharing expensed relating to patent maintenance, defense and prosecution, incurred	$ 0.5	$ 0.6
Cost sharing expensed relating to patent maintenance, defense and prosecution, accrued	$ 0.9		$ 2.8
Research and Office Facility [Member]
Contingencies And Commitments [Line Items]
Operating lease number of sublet portions \| Sublease	1

XML 42 R32.htm IDEA: XBRL DOCUMENT

Significant Contracts - Additional Information (Detail)
€ in Millions, SFr in Millions

1 Months Ended

3 Months Ended

12 Months Ended

Apr. 30, 2014

USD ($)

Apr. 30, 2014

CHF (SFr)

Mar. 31, 2017

USD ($)

Mar. 31, 2016

USD ($)

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Nov. 30, 2014

EUR (€)

Nov. 30, 2014

USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and development expense

^[1]

$ 14,805,000

$ 6,012,000

Non-current deferred revenue

$ 78,311,000

$ 77,646,000

Date of joint venture agreement

Dec. 19, 2015

Equity method investment

$ 0

Stock-based compensation expense

3,746,000

1,022,000

Casebia Therapeutics LLP [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and development expense

1,100,000

Revenue from collaboration agreement

1,200,000

Non-current deferred revenue

$ 400,000

500,000

Date of formation of joint venture entity

Feb. 12, 2016

Unrecognized equity method losses in excess of Company's interest

$ 6,500,000

4,000,000

Stock-based compensation expense

500,000

Net loss of joint venture

5,500,000

73,800,000

Casebia Therapeutics LLP [Member] | Fair Value of CRISPR License Acquired [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and development expense

71,400,000

Vertex Pharmaceuticals Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and development expense

2,600,000

600,000

Revenue from collaboration agreement

1,500,000

500,000

Non-current deferred revenue

77,900,000

77,100,000

Patent Assignment Agreement [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and development expense

19,000

Clinical milestone payment payable

€ 0.3

$ 400,000

CRISPR-Charpentier License Agreement [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront fees paid for license

$ 100,000

SFr 0.1

Annual payments for consulting agreement

$ 0

Research and development expense

300,000

TRACR-Charpentier License Agreement [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research and development expense

$ 0

[1]	Including the following amounts of research and development expense with a related party, see Note 11:

XML 43 R33.htm IDEA: XBRL DOCUMENT

Share Capital - Additional Information (Detail) - SFr / shares	Mar. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Common stock, shares authorized	40,258,364
Common shares, par value	SFr 0.03	SFr 0.03
Treasury stock, shares	444,873	444,873
Unvested Unissued Restricted Share Awards [Member]
Class of Stock [Line Items]
Unvested unissued restricted common stock	80,987

XML 44 R34.htm IDEA: XBRL DOCUMENT

Share Capital - Schedule of Conditional Capital Reserved for Future Issuance (Detail) - shares	Mar. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Conditional capital reserved for future issuance	15,325,607	15,325,607
Employee Purchase Plans [Member]
Class of Stock [Line Items]
Conditional capital reserved for future issuance	413,226	413,226
Bonds and Similar Debt Instruments [Member]
Class of Stock [Line Items]
Conditional capital reserved for future issuance	4,919,700	4,919,700
Unvested Unissued Restricted Stock [Member]
Class of Stock [Line Items]
Conditional capital reserved for future issuance	166,667	166,667
Outstanding Stock Options [Member]
Class of Stock [Line Items]
Conditional capital reserved for future issuance	4,829,891	4,535,371
Stock Option Plan [Member]
Class of Stock [Line Items]
Conditional capital reserved for future issuance	4,996,123	5,290,643

XML 45 R35.htm IDEA: XBRL DOCUMENT

Equity-based Compensation - Equity-based Compensation Expense - Additional Information (Detail) - Stock Options and Restricted Stock Awards [Member]	3 Months Ended
	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, options, vesting period	4 years
Share-based Compensation, options, vesting terms	Vest over four years with 25% vesting on the first anniversary of service commencement and the remaining 75% vesting monthly thereafter
Vesting Percentage on First Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, options, vesting percentage	25.00%
Vesting Percentage after First Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, options, vesting percentage	75.00%

XML 46 R36.htm IDEA: XBRL DOCUMENT

Equity-based Compensation - Schedule of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 3,746	$ 1,022
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	1,730	638
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	1,570	$ 384
Loss from Equity Method Investment [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 446

XML 47 R37.htm IDEA: XBRL DOCUMENT

Equity-based Compensation - Fair Value of Employee and Non-employee Stock Option Award on the Grant Date Using the Black-Scholes Option-Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average expected volatility	73.00%	77.50%
Expected term (in years)	6 years	6 years
Risk free interest rate	2.20%	1.50%
Expected dividend yield	0.00%	0.00%
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average expected volatility	81.00%
Expected term (in years)	10 years	0 years
Risk free interest rate	2.40%
Expected dividend yield	0.00%

XML 48 R38.htm IDEA: XBRL DOCUMENT

Equity-based Compensation - Summary of Stock Option Activity for Employees and Non-employees (Detail) - Employees and Non-employees [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options, Outstanding, Beginning Balance	4,535,371
Stock Options, Granted	440,032
Stock Options, Exercised	(4,690)
Stock Options, Cancelled or forfeited	(140,822)
Stock Options, Outstanding, Ending Balance	4,829,891	4,535,371
Stock Options, Exercisable	1,289,490
Stock Options, Vested or expected to vest	4,755,902
Weighted-Average Exercise Price, Outstanding, Beginning Balance	$ 8.38
Weighted-Average Exercise Price, Granted	20.78
Weighted-Average Exercise Price, Exercised	4.24
Weighted-Average Exercise Price, Cancelled or forfeited	5.14
Weighted-Average Exercise Price, Outstanding, Ending Balance	9.59	$ 8.38
Weighted-Average Exercise Price, Exercisable	4.27
Weighted-Average Exercise Price, Vested or expected to vest	$ 9.51
Weighted-Average Remaining Contractual Term	9 years	9 years 1 month 6 days
Weighted-Average Remaining Contractual Term, Exercisable	8 years 7 months 6 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	9 years
Outstanding at December 31, 2016	$ 58,960	$ 53,966
Exercisable at March 31, 2017	22,568
Vested or expected to vest at March 31, 2017 (1)	$ 58,417

XML 49 R39.htm IDEA: XBRL DOCUMENT

Equity-based Compensation - Share Based Payment Activity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation expense	$ 28,900
Equity-based compensation expense not yet recognized, weighted-average service period for recognition	3 years 2 months 12 days
Stock-based compensation expense	$ 3,746	$ 1,022
Founders' [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-Average Exercise Price, Vested or expected to vest			$ 12.65
Stock-based compensation expense	$ 200	$ 0
Fay Corp Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation, number of shares issued			290,400
Fay Corp Awards [Member] \| Founders' [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Transfer of vested shares			268,093
Performance-Based [Member] \| Vesting Percentage on First Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options, Granted	15,000	13,333
Share-based compensation, options, vested	284,372
Share-based compensation, options, deemed probable of vesting	0
Performance-Based [Member] \| Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock, granted	0
Restricted stock, vested	50,000
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense not yet recognized, weighted-average service period for recognition	1 year 2 months 12 days
Total fair value of vested restricted common shares	$ 2,300
Total unrecognized compensation expenses	$ 6,400
Restricted stock, vested	114,380

XML 50 R40.htm IDEA: XBRL DOCUMENT

Equity-based Compensation - Summary of the Company's Restricted Stock Activity (Detail) - Restricted Stock Awards [Member]	3 Months Ended
	Mar. 31, 2017 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted common shares, Number of Shares, Beginning Balance	740,223
Unvested restricted common shares, Number of Shares, Vested	(114,380)
Unvested restricted common shares, Number of Shares, Ending Balance	625,843
Unvested restricted common shares, Weighted-Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 3.84
Unvested restricted common shares, Weighted-Average Grant Date Fair Value, Vested \| $ / shares	4.02
Unvested restricted common shares, Weighted-Average Grant Date Fair Value, Ending Balance \| $ / shares	$ 3.81
Reflected as Outstanding Upon Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted common shares, Number of Shares, Beginning Balance	89,367
Unvested restricted common shares, Number of Shares, Vested	(8,380)
Unvested restricted common shares, Number of Shares, Ending Balance	80,987
Reflected as Outstanding Upon Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted common shares, Number of Shares, Beginning Balance	650,856
Unvested restricted common shares, Number of Shares, Vested	(106,000)
Unvested restricted common shares, Number of Shares, Ending Balance	544,856

XML 51 R41.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income tax provision	$ 279	$ 76
Effective income tax rate	1.30%	0.90%

XML 52 R42.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Dec. 31, 2016

Research and development expense

^[1]

$ 14,805

$ 6,012

Accounts receivable, related party amount, current

1,057

$ 752

Other current assets, related party amount

577

Deferred revenue related party amount

420

527

Casebia Therapeutics LLP [Member]

Revenue from collaboration agreement

1,200

Research and development expense

1,100

Bayer Healthcare LLC [Member]

Sublicense fees payable

200

500

Bayer Healthcare LLC [Member] | Research and Development [Member]

Sublicense fees recorded

$ 300

Bayer Healthcare LLC [Member] | Casebia Therapeutics LLP [Member]

Revenue from collaboration agreement

1,200

Research and development expense

1,100

Accounts receivable, related party amount, current

1,100

800

Other current assets, related party amount

600

Deferred revenue related party amount

$ 400

$ 500

[1]	Including the following amounts of research and development expense with a related party, see Note 11:

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 110 197 1 true 47 0 false 8 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.crisprtx.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.crisprtx.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.crisprtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss Sheet http://www.crisprtx.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statement of Operations and Comprehensive Loss Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss (Parenthetical) Sheet http://www.crisprtx.com/taxonomy/role/StatementOfIncomeAlternativeParenthetical Condensed Consolidated Statement of Operations and Comprehensive Loss (Parenthetical) Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.crisprtx.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 108 - Disclosure - Organization and Operations Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Organization and Operations Notes 7 false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 8 false false R9.htm 110 - Disclosure - Property and Equipment, net Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock Property and Equipment, net Notes 9 false false R10.htm 111 - Disclosure - Accrued Expenses Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses Notes 10 false false R11.htm 112 - Disclosure - Convertible Loans Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Convertible Loans Notes 11 false false R12.htm 113 - Disclosure - Commitments and Contingencies Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 12 false false R13.htm 114 - Disclosure - Significant Contracts Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock Significant Contracts Notes 13 false false R14.htm 115 - Disclosure - Share Capital Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Share Capital Notes 14 false false R15.htm 116 - Disclosure - Equity-based Compensation Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Equity-based Compensation Notes 15 false false R16.htm 117 - Disclosure - Income Taxes Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 16 false false R17.htm 118 - Disclosure - Related Party Transactions Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 17 false false R18.htm 119 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 18 false false R19.htm 120 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) Tables http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 19 false false R20.htm 121 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables Property and Equipment, net (Tables) Tables http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock 20 false false R21.htm 122 - Disclosure - Accrued Expenses (Tables) Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) Tables http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 21 false false R22.htm 123 - Disclosure - Share Capital (Tables) Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Share Capital (Tables) Tables http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 22 false false R23.htm 124 - Disclosure - Equity-based Compensation (Tables) Sheet http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Equity-based Compensation (Tables) Tables http://www.crisprtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 23 false false R24.htm 125 - Disclosure - Organization and Operations - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureOrganizationAndOperationsAdditionalInformation Organization and Operations - Additional Information (Detail) Details 24 false false R25.htm 126 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfNetLossPerShare Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Detail) Details 26 false false R27.htm 128 - Disclosure - Property and Equipment, net - Summary of Property and Equipment, Net (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNet Property and Equipment, net - Summary of Property and Equipment, Net (Detail) Details 27 false false R28.htm 129 - Disclosure - Property and Equipment, net - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation Property and Equipment, net - Additional Information (Detail) Details 28 false false R29.htm 130 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 29 false false R30.htm 131 - Disclosure - Convertible Loans - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureConvertibleLoansAdditionalInformation Convertible Loans - Additional Information (Detail) Details 30 false false R31.htm 132 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 31 false false R32.htm 133 - Disclosure - Significant Contracts - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureSignificantContractsAdditionalInformation Significant Contracts - Additional Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Share Capital - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureShareCapitalAdditionalInformation Share Capital - Additional Information (Detail) Details 33 false false R34.htm 135 - Disclosure - Share Capital - Schedule of Conditional Capital Reserved for Future Issuance (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureShareCapitalScheduleOfConditionalCapitalReservedForFutureIssuance Share Capital - Schedule of Conditional Capital Reserved for Future Issuance (Detail) Details 34 false false R35.htm 136 - Disclosure - Equity-based Compensation - Equity-based Compensation Expense - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureEquitybasedCompensationEquitybasedCompensationExpenseAdditionalInformation Equity-based Compensation - Equity-based Compensation Expense - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Equity-based Compensation - Schedule of Stock-Based Compensation Expense (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureEquitybasedCompensationScheduleOfStockBasedCompensationExpense Equity-based Compensation - Schedule of Stock-Based Compensation Expense (Detail) Details 36 false false R37.htm 138 - Disclosure - Equity-based Compensation - Fair Value of Employee and Non-employee Stock Option Award on the Grant Date Using the Black-Scholes Option-Pricing Model (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureEquitybasedCompensationFairValueOfEmployeeAndNonemployeeStockOptionAwardOnTheGrantDateUsingTheBlackScholesOptionPricingModel Equity-based Compensation - Fair Value of Employee and Non-employee Stock Option Award on the Grant Date Using the Black-Scholes Option-Pricing Model (Detail) Details 37 false false R38.htm 139 - Disclosure - Equity-based Compensation - Summary of Stock Option Activity for Employees and Non-employees (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfStockOptionActivityForEmployeesAndNonemployees Equity-based Compensation - Summary of Stock Option Activity for Employees and Non-employees (Detail) Details 38 false false R39.htm 140 - Disclosure - Equity-based Compensation - Share Based Payment Activity - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureEquitybasedCompensationShareBasedPaymentActivityAdditionalInformation Equity-based Compensation - Share Based Payment Activity - Additional Information (Detail) Details 39 false false R40.htm 141 - Disclosure - Equity-based Compensation - Summary of the Company's Restricted Stock Activity (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureEquitybasedCompensationSummaryOfTheCompanysRestrictedStockActivity Equity-based Compensation - Summary of the Company's Restricted Stock Activity (Detail) Details 40 false false R41.htm 142 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 41 false false R42.htm 143 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.crisprtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 42 false false All Reports Book All Reports crsp-20170331.xml crsp-20170331.xsd crsp-20170331_cal.xml crsp-20170331_def.xml crsp-20170331_lab.xml crsp-20170331_pre.xml true true ZIP 59 0001193125-17-166631-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-17-166631-xbrl.zip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

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer

☒ (Do not check if smaller reporting company)

Smaller Reporting Company